

CURRICULUM VITAE

MURALI MOHAN YALLAPU, PhD

Associate Professor (Tenured)

Department of Immunology and Microbiology

School of Medicine

University of Texas Rio Grande Valley

McAllen, TX 78503, USA

E-mail: murali.yallapu@utrgv.edu

Ph: 901-296-1734

Ph: 901791-7479

EDUCATION:

Undergraduate: Chemistry, Physics and Mathematics, Sri Krishnadevaraya University,
Anantapur, India, **Bachelor of Science**, June 1993-April 1996, July 1996.

Graduate School: Polymer Science & Technology, Sri Krishnadevaraya University,
Anantapur, India, **Mater of Science**, June 1997-June 1999, July 1999.

Polymer Science & Technology, Sri Krishnadevaraya University,
Anantapur, India, **Ph.D.** March 2001-March 2005, March 2005.

UNIVERSITY (AND COLLEGE) APPOINTMENTS:

2013-2015 Assistant Professor (Research track), Department of Pharmaceutical Sciences, College of
Pharmacy, University of Tennessee Health Science Center, Memphis, USA
2015-2019. Assistant Professor (Tenure track), Department of Pharmaceutical Sciences, College of
Pharmacy, University of Tennessee Health Science Center, Memphis, USA
2019-Pre Associate Professor (Tenured), Department of Immunology and Microbiology, College of
Medicine, University of Texas Rio Grande Valley, Edinburg/McAllen, TX, USA

PRACTICE/PROFESSIONAL EXPERIENCE:

2011-2013 Staff Scientist, Cancer Biology Research Center, Sanford Research/USD, Sioux
Falls, USA
2008-2011 Postdoctoral Fellow, Cancer Biology Research Center, Sanford Research/USD, Sioux Falls, USA
2007-2008 Postdoctoral Fellow, Department of Biomedical Engineering, ND-20, Lerner
Research Institute Cleveland, OH, USA
2006-2007 Postdoctoral Fellow, Department of Pharmaceutical Sciences, University of
Nebraska Medical Center, Omaha, USA
2001-2003 Project Fellow, Dept. of Polymer Science & Technology, Anantapur, India

FUNDING:

1R01CA206069-01 (PI: Chauhan; **Yallapu-Co-I**) 06/01/2016-05/31/2021 1.2-1.8 months (CY)
NIH-NCI R01 \$250,000

Development of Targeted Nanotechnology Platform for Pancreatic Cancer
To develop efficient targeted therapeutic formulation for pancreatic cancer
Overlap: None.

1R01CA199708-01A1 (PI: Chauhan; **Yallapu-Co-I**) 06/01/2016-05/31/2021 1.2-1.8 months (CY)
NIH-NCI R01 \$250,000

MUC13 Targeted Novel Paclitaxel Nanoparticle Formulation for Pancreatic Cancer
To delineate MUC13 targeted therapeutics for Pancreatic Cancer
Overlap: None.

1R01CA204552-01 (PI: Chauhan; **Yallapu-Co-I**) 06/01/2016-05/31/2021 0.6-1.2 months (CY)
NIH-NCI R01 \$250,000
MUC13 in Colorectal Cancer
To examine the role of MUC13 in colorectal cancer in African American, American Indian and Caucasian. Overlap: None.

RGV0000679 01/28/2020-12/31/2020
Kosten Foundation-Pancreatic Cancer Research
Novel Therapeutic Approach for Pancreatic Cancer Treatment
PI: Subhash C Chauhan
Co-I: Yallapu

HONORS/AWARDS:

1999 **Prof. A. Kameswara Rao's Gold Medal** for the Year 1999
1999 First Rank in M.Sc. Polymer Science Batch 1997-1999
2006 **Cover Page Image of Research Work** in the Journal "Macromolecular Rapid
Communication 2006, 27, 1346-1354.
(http://www3.interscience.wiley.com/journal/10003270/home/cover/2006_27_16.html)
2008 Selected for "**Who's Who in Science and Engineering**" 10th Anniversary
Edition (2007) by Marquis Who's Who, USA
2005-2010 **Top 25 articles within the journal:** Several of my articles have been
occupied top 25 articles in Elsevier Journals (Respective journals)
2010 Top 10 most viewed articles within in the Journal of Ovarian Research
2016 **Personalized Nanomedicine Investigator Award** by Personalized
Nanomedicine Society, Miami
2018 **CIPA International Presenter**, Conception, Chile <http://www.cipachile.cl/cipa-organiza-simposio-internacional/>
2018 **Outstanding Mentor Academy Inductee**, University of Tennessee Health Science Center,
Memphis.

Journal/Book Research Cover Pages:

SOCIETY MEMBERSHIPS:

2009-Pres. Member, American Association for Cancer Research (AACR)
2009-2011. Controlled release Society (CRS)
2010 Life Member, Asian Polymer Association (APA)
2013-Pres. American Association of Colleges of Pharmacy (ACCP)

TEACHING EXPERIENCE:

SOM-UTRGV Class size 50 Fall 2019

Attack & Defense Two modules:

19.3 Nano Immunotherapy:

- 19.3.1 Provide nanoparticle technology and its clinical relevance in immunotherapy
- 19.3.2 Delineate the different types of nanoparticles and their targetability and bioavailability for improved immunotherapy outcome
- 19.3.3 Identify suitable biodegradable nanoparticles for immunotherapies
- 19.3.4 Strategic evaluations of nanoparticles for cancer immunotherapy.

19.7. Side Effects of Drugs, Immunotherapy, and Nano Vaccines

- 19.7.1 Identify and explain possible systemic side effects of immunotherapy drugs/vaccines

19.7.2 Describe the Nanovectors use for Vaccine Delivery

19.7.3 Discuss the Strategic antibody mediated targeted therapeutic vaccine development and hurdles approach

Spring 2018 & Fall 2018

PHSC 123 – Pharmaceutics

P1 Spring

Students: 190; 2 Hrs

This course is intended to provide a foundation in the principles, which are fundamental to the study of pharmaceutics and drug delivery, including physical pharmacy and dosage form design. Students will learn about the design, composition and proper use of dosage forms, including manufactured commercial products for the mass market and extemporaneously compounded preparations for individual patients. An emphasis will be placed on how to compound solid, liquid, and semi-solid dosage forms.

Fall 2017

PHCY 1101

P1 Fall

Students: 190; 3 Hrs

Fundamentals of Drug Action

This course will introduce the first year student pharmacist to the world of drugs, biologics, and dietary supplements, in which, the physical and chemical characteristics of molecules that define drugs will be taught. Students will also learn fundamental principles and factors/conditions that affect drugs action and disposition as well as drug-drug interaction and toxicity. This course will serve as a foundation for other courses in the pharmacy curriculum. Specifically, it will be foundational for Pharmacokinetics and Pharmacodynamics, as well as, for Medicinal Chemistry, Pharmacology, and Therapeutics aspects of all the disease modules that will follow in the curriculum.

Fall 2017

PHCY 1100

P1 Fall

Students: 190; 4 Hrs

BIOCHEMISTRY FOR PHARMACISTS

Biochemistry is a required course in the Pharm.D. curriculum. The course is designed to provide students with foundational knowledge of the basic concepts of biochemistry pertinent for understanding of the biochemical basis of disease and the molecular underpinnings of drug action. Topics covered in the course include: structure and properties of nucleic acids, proteins, lipids and carbohydrates as the biological macromolecules essential to life; enzyme catalysis and inhibition; structure and function of biological membranes; major metabolic pathways and their regulation; and basic principles of signal transduction. Presentations of clinical correlates such as molecular alterations in selected human diseases and examples of drug therapies discussed in biochemical context are incorporated to highlight the clinical aspects of biochemistry and to demonstrate the importance of biochemistry for pharmacy.

Spring 2018 and Fall 2018

PHSC 222 Pharmacogenomics

P2 Fall

Students: ~190; 1 Hr

This course will introduce emerging information regarding genetic variation in the human genome and how this information can be applied to the fundamental precepts of pharmacokinetics (adsorption, metabolism, distribution, and excretion) and pharmacodynamics as well as applied pharmacotherapy. Moreover, the impact of genetic variation on disease susceptibility and next generation drug discovery and development will be explored. Finally, important ethical considerations when testing for and applying clinically-relevant genetic information will be discussed.

Spring 2014, Spring 2015, Spring 2016, Spring 2017, Spring 2018

PHAC911

Spring 2014

3 or 4 Credits course

Students: 4-9; 18 Hrs

Instructor

DELIVERY AND BIOCOMPATIBILITY OF PROTEIN AND NUCLEIC ACID DRUGS

This course is designed to teach students about the delivery and biocompatibility of proteins, peptides and nucleic acid drugs and dosage form design. Topics will include: (i) design, synthesis and characterization of polymer systems, (ii) biocompatibility, (iii) protein and peptide drug delivery, (iv) nucleic acid drug delivery, and (v) oligonucleotide and gene therapy.

Fall 2015, Fall 2016, Fall 2017, Fall 2018

PHCY 115

Fall 2015

3 Credits

Students: 10-12; 18 Hrs

Instructor/Facilitator

FOUNDATIONS OF PHARMACY

This course provides student pharmacists with an introduction to the profession of pharmacy. Materials center on health delivery models, the environment in which health care is rendered, and interprofessional care with a focus on the roles of the pharmacist. Students learn about a variety of career opportunities and will self-assess their potential interest using the APhA Career Pathways Program. This course will also enhance the student's understanding of professionalism and the responsibility of a pharmacist in society and the health care system. The course examines the role of human professional behaviors and values as mediators of health and illness, with a focus on health care disparities and health literacy.

Polymer Science and Polymer Coatings: 12 Students

Sri Krishnadevaraya University, Anantapur, 2001-2003

VISITING PROFESSORSHIPS AND INVITED LECTURES:

2005-2006 Postdoctoral Fellow, Gwangju Institute of Science & Technology, Gwangju, South Korea

EDITORIAL APPOINTMENTS AND HONORS:

- 2010-Pres. Member of Editorial Board of the Journal of Biomaterials and Nanobiotechnology
- 2010-Pres. Member of Editorial Board of the Journal of Biomedical Science and Engineering
- 2010-Pres. Member of Editorial Board of the Journal of Nanomedicine & Biotherapeutic Discovery
- 2014-Pres. Member of Editorial Board of the Drug Delivery Letters
- 2014-Pres. Member of Editorial Board of the Journal of Nanopharmaceutics and Drug Delivery
- 2014-Pres. Member of Editorial Board of Scientific Reports
- 2013 Reviewer, North West Cancer Research Grants, Liverpool, UK
- 2015 Reviewer, The Danish Council for Independent Research, Bredgade 40, DK-1260 København K Denmark
- 2014-2015 Regional Editor of the Current Bio nanotechnology
- 2014 External Thesis Evaluation-"Design and Development of Novel Multi Drug Delivery System for Biomedical Application" submitted by Tshwane University of Technology, Lynnwoodridge, RSA
- 2014 **External Thesis Evaluation**-"Development and evaluation of curcumin-loaded Pluronic F127 nanoformulation" submitted by The University of Western Australia, Crawley WA 6009
- 2015 Panel Member-Cancer Nanotechnology: Joint Southeastern/Southwest Regional Meeting, Cook Convention Center, Mississippi Room, November 4-7, 2015.
- 2016 Reviewer NIH- Biomaterials and Biointerfaces Study Section (BMBI): 06/16/2016-06/17/2016, Admiral Fell Inn, Baltimore, MD
- 2016 2016 Graduation Research Day Poster Judge, April 8, 2016, The University of Tennessee Health Science Center, TN, USA
- 2016 Reviewer NIH- ZRG1-SBIB-Z-58 09/30/2016- 09/31/2016, at Serrano Hotel, San Francisco, CA.
- 2016 UTHSC-Postdoc Travel Award Judge, December 8, 2016, The University of Tennessee Health Science Center, TN, USA
- 2016 UTHSC-Postdoc Oral Presentation Judge, December 8, 2016. The University of Tennessee Health Science Center, TN, USA
- 2017 UTHSC-Graduate Research Day, Poster Presentation Judge, April 7, 2017, UTHSC Alumni Center, The University of Tennessee Health Science Center, TN, USA.
- 2016 Reviewer NIH- ZRG1-SBIB-Z-58 09/30/2016- 09/31/2016, Serrano Hotel, San Francisco, CA.
- 2017 Reviewer NIH- DT Study Section, 02/06/2017 - 02/07/2017, The Ritz-Carlton, Pentagon City, VA.
- 2017 Reviewer NIH- BMIT-A, 02/08/2017, Mail Reviewer.
- 2017 Reviewer ZRG1 OTC-T (10) B, Small Business: Cancer Drug Development and Therapeutics, 06/22/2017-06/23/2017, Courtyard by Marriott, Chevy Chase, MD.

- 2017 External PhD Thesis Examiner (Highly flexible carbon fibre fabric based nanostructured hybrids for high performance energy storage systems-Murat Cakici, SID: 410008939), The University of Sydney.
- 2017 External MSc Thesis Examiner (Design and in vitro analysis of PEG based multi-drug delivery system for combination therapy in treatment of breast cancer-Victoria Oluwaseun Fasiku, 28177088), North West University, South Africa.
- 2018 External PhD Thesis Examiner (Design and biological evaluation of acrylated polyethylene glycol gel containing acarbose- S.J Owonubi, 27264610), North West University, South Africa.
- 2107 10/19/2017 at CSR ZRG1-SBIB-Q-58 Panel Reviewer
- 2018 03/08/2018 at CSR ZRG1-SBIB-Q-58 Panel Reviewer
- 2018 04/19/2018 at CSR ZRG1-SBIB-Q-90 Panel Reviewer
- 2018 2018/10 at CSR ZRG1-SBIB-Q-58 Panel Reviewer
- 2018 May 2018, Grant Overseas Reviewer, National Health & Medical Research Council, Australia
- 2018 Reviewer, Khalifa University of Science & Technology Competitive Internal Research Awards
- 2019 2018/10 at CSR ZRG1-SBIB-Q-58 Panel Reviewer
- 2019 Reviewer, Office of Vice Chancellor for Research and Graduate Studies, Research Department, University of Sharjah, United Arab Emirates
- 2017-Pre Reviewer, Pharmaceutics Journal Travel Awards to Graduate Student and Postdoctoral Fellows, MDPI Publications

Journal/Book Research Cover Pages:



Macromolecular Rapid Communication; Macromolecular Bioscience; Colloid and Interface Science; Journal of Biomaterials and Nanobiotechnology; Recent Advances in Nanoscience and Technology Current Advances in Gynecological Oncology, ACS Omega, Pharmaceutics.

Reviewer for the Journals (2012-Pres)

- Biochemical Pharmacology
- Biomaterials
- Biomacromolecules

BMC Cancer
Cancer Medicine
Nanomedicine
Nanomedicine: Nanotechnology, Biology and Medicine
International Journal of Nanomedicine
ACS Nano
Drug Discovery Today
Molecular Pharmaceutics
Scientific Reports
Journal of Colloid and Interface Sciences
Journal of Controlled Release
Journal of Microbiological Methods (2018-pres)
Drug Delivery Letters
Chemical Communications
Colloids and Interface Science
RSC Advances
Materials Letters
Journal of Biomedical Materials Research: Part A
European Journal of Medicinal Chemistry
Current Medicinal Chemistry
Drug Design, Development and Therapy
OncoTargets and Therapy
ACS Biomaterials Science & Engineering,
International Journal of Pharmaceutics, etc.
Pharmaceutics

RESIDENTS/FELLOWS/GRADUATE STUDENTS TRAINED:

Mentor/Co-Mentoring/Guidance:

1. Miss. Amber Cruise (2009, Summer), High School, Sanford Research/USD, South Dakota, SD
2. Miss. Hilary Newby (2009, Summer), High School, Sanford Research/USD, South Dakota, SD
3. Mr. Mitch Ray Dobberpuhl (2009 & 2010 Summer), University of South Dakota, Medical Student, Sanford Research/USD, South Dakota, SD
4. Miss. K. Vimala, Ph.D. Student (2006-2010), Sri Krishnadevaraya University, India
5. Mr. K. Varaprasad, Ph.D. Student (2005-2009), Sri Krishnadevaraya University, India
6. Mr. S. Ravindra, Ph.D. Student (2006-2010), Sri Krishnadevaraya University, India
7. N. Narayana Reddy, Ph.D. Student (2006-2010), Sri Krishnadevaraya University, India
8. Mr. K. Samba Sivudu, Ph.D./Postdoc (2004-2008/2009), Sri Krishnadevaraya University, India
9. Miss. Varsha Thomas, Ph.D. Student (2006-2010), Government Science Model College, Jabalpur, India
10. Miss. Neeraj Chauhan, MS/Ph.D. Student (2010-2017), University of Tennessee Health Science Center, Memphis
11. Vaibhav Gandhi, Ph.D. Student (2014-2015), University of Tennessee Health Science Center, Memphis
12. Miss. Nia R. Johnson, Nursing Student, Summer Intern (2014) University of Tennessee Health Science Center, Memphis
13. Dr. Vijaya Kumar Naidu, Visiting Postdoc (2015-2016), University of Tennessee Health Science Center, Memphis
14. Mr. Ren Lovett, Nursing Student, Summer Intern (2015), University of Tennessee Health Science Center, Memphis
15. Mr. Prashanth Bhusetty, Postdoc (2015-2019), University of Tennessee Health Science Center, & University of Texas Rio Grande Valley
16. Miss. Pallabita Chowdhury, Graduate Student (2015-2020), University of Tennessee Health Science Center, Memphis, Graduated in April 2020
17. Miss. Elham Hatami, Graduate Student (2016-2020), University of Tennessee Health Science Center, Memphis, Graduated in Feb 2020
18. Miss. Yuqing Gong, Graduate Student (2016-2020), University of Tennessee Health Science Center, Memphis, Graduated in Feb 2020

19. Mr. Nirnoy Dan, MS Student (2016-2019), University of Tennessee Health Science Center, Memphis (Trained for Nanotechnology)
20. Miss. Deanna Nichole Shields (UOM College Student, 2018-2019), University of Tennessee Health Science Center, Memphis
21. Miss. Nafisa (UTHSC MS Student Work Study program, 2018), University of Tennessee Health Science Center, Memphis
22. Mr. Nicholas (MS Pharmacology Student – Work Study program, 2018), University of Tennessee Health Science Center, Memphis
23. Mr. Sumeet C. Chauhan (UOM College Student, 2018-2019), University of Tennessee Health Science Center, Memphis
24. Dr. Neeraj Chauhan, (2019-Pre), University of Texas Rio Grande Valley, McAllen, TX

RESEARCH AND OTHER EXTERNAL SUPPORT:

Ongoing Research Support

NIH/NCI 1R01CA210192-01 (Chauhan-PI, Yallapu-co-I) 06/24/2016 – 05/31/2021 (15%)
Targeted Nanotherapy for Pancreatic Cancer

The long-term goal of the proposed research is to develop a targeted paclitaxel nanotherapy that can be used for the treatment of pancreatic cancer (PanCa) in combination with Gemcitabine. Such antibody guided nanotherapy targets tumor microenvironment and regulate lipid profiles in PanCa cells. This strategy will improve therapeutic outcomes of localized and metastatic PanCa and clinical translation of this approach will be easy and quick as proposed studies are based on recent clinical observations. No overlap

NIH/NCI 1R01CA206069-01A1 (Chauhan-PI, Yallapu-co-I) 06/24/2016 – 05/31/2021 (15%)
Development of a Targeted Nanotechnology platform for Pancreatic Cancer

This project is aimed to develop an innovative, targeted magnetic nanoparticle mediated therapeutic and imaging approach for PanCa using a novel anti-MUC13 humanized/monoclonal antibody. Development of this novel targeted approach will advance diagnosis and therapy of PanCa to reduce the morbidity and mortality caused by this devastating disease. No overlap

NIH/NCI 1R01CA204552-01 (Chauhan-PI, Yallapu-co-I) 07/11/2016-05/31/2021 (10%)
MUC13 Mucin in Colorectal Cancer Health Disparity

This grant will investigate how various intrinsic factors induce aberrant/altered subcellular localization of Mucin (MUC13), in clinically relevant CRC cell line models, which can be associated with disease stage, prognosis and metastasis. The results obtained from this work will lead to a novel molecular signature for early detection of aggressive and metastatic CRC in AA and AI. Further, this study will provide important insights regarding MUC13 etiology in CRC and help in designing preventive and therapeutic strategies to reduce CRC mortality and CRC health disparity in underserved populations. No overlap

Completed Research Support

PC130870 (PI: Chauhan; Yallapu– Co-I) 09/21/2014-08/20/2017 0.3 (CY) months
DOD \$125,000

A Novel Therapeutic Modality for Advanced Stage Prostate Cancer Treatment
To investigate the ormeloxifene use in prostate cancer therapeutics.
Overlap: None.

NIH/NCI K22CA174841 (PI: Murali Yallapu) 02/12/2015-01/31/2018
Docetaxel Loaded Magnetic Nanoparticles for Prostate Cancer

The central goal of this grant is to achieve enhanced uptake of docetaxel (Dtxl) loaded MNPs in cancer cells/tumors which will improve the effectiveness of treatment of Dtxl for PrCa. This approach combines therapeutic and diagnostic/imaging properties that has tremendous potential to advance therapy and imaging of PrCa. No overlap

CORNET GRANT 1 UTHSC

To develop dual drug loaded NPs formulation for BC
No overlap

CORNET GRANT 2 UTHSC

To develop TNF-alpha Nanogel particles for H&N cancers

No overlap

Seed Grant

Dean's Enhancement Program for Instrument Grants (Yallapu-PI) 07/01/2014 06/30/2015, College of Pharmacy, UTHSC, Memphis

UT 14-0558

(PI: Chauhan)

03/01/2014-Current

Kosten Foundation, Memphis

Pancreatic Cancer Treatment

Role: Co-Investigator

Seed Grant

Dean's Enhancement Program for Instrument Grant (Yallapu-PI) 07/01/2014-06/30/2015, College of Pharmacy, UTHSC, Memphis

Seed Grant

Dean's Research Grant (Yallapu-PI) 07/01/2013 06/30/2014,
College of Pharmacy, UTHSC, Memphis

Seed Grant

Dean's Enhancement Program for Instrument Grants (Yallapu-PI) 07/01/2013 06/30/2014, College of Pharmacy, UTHSC, Memphis

Seed Grant

Young Investigator Sanford Seed Research Grant (Yallapu-PI) 07/01/2012-06/30/2013

DoD New Investigator Award

(Yallapu-Postdoc)

02/10/2008-30/09/2011

PSMA Targeted Nano-Radioimmunotherapy using Curcumin for Advanced Prostate Cancer

Research Description

My research goal is primarily to study the fate of drug nanoformulations that leads to novel insights of various biological factors and properties responsible for effective and targeted delivery. At the translational front, my work focuses on identification of novel therapeutic treatment strategies including development of targeted delivery systems for therapeutic macromolecules; designing of anti-tumor drug formulations for improving target-ability and efficiency; developing novel multi-functional self-assembling polymer materials; and novel applications of these materials for photodynamic, hyperthermia and imaging in cancer therapeutics. The overall goal of my research is to use these studied materials to devise advanced delivery systems that can be tailored to meet the needs of individual cancer patient. Despite recent advances in diagnostic techniques and treatment modalities, cancer remains the second leading cause of mortality in the United States. Development of resistance to therapeutic drugs is a major obstacle in clinical outcome. Thus, developing novel therapeutic strategies are required in overcoming the heterogeneous functions of tumor drug resistance. Therefore, my research interest is to investigate improved therapeutic potential of clinical drug(s) using nanotechnology. Nanoparticle (nanotechnology) drug delivery systems could prove to be a promising adjunct to improve the therapeutic effect by maximizing the permeability and retention of drugs in solid tumors and thus can reduce non-specific toxicity. Additionally, drug nanoformulations also reduce the chemotherapeutic dose required for therapy due to improved targeting of drug, increased intracellular accumulation and sustained release for superior pharmacological actions. These characteristics significantly reduce the chemotherapy related adverse effects and relapse. All these prompted us to put forward more interest to generate safe and effective drug nanoformulations for cancer therapy. I have recently developed and patented a unique magnetic nanoparticle for drug delivery application which hold great potential to improve the therapeutic efficacy of existing natural and chemotherapeutic drugs. Some of my published and un-published data on this nanoformulation exhibits improved drug accumulation in target tissues.

BOOKS AND BOOK CHAPTERS:

1. Murali Mohan Yallapu, Maram K Reddy, Vinod Labhassetwar, Nanogels : Chemistry to Drug Delivery in Nanotechnology for Drug Delivery Applications, in “Biomedical Applications of Nanotechnology” Editors: Vinod Labhassetwar and Diandra L. Leslie-Pelecky, John-Wiley, 131-171 (2007)
2. K. Sambasivudu, Y. Murali Mohan and K. Mohana Raju, Rational Synthesis Approaches to Metal Nanoparticles and Polymer Metal Nanocomposites, in “Recent Advances in Nanoscience and Nanotechnology”, Editors: S.K. Bajpai and Murali Mohan Yallapu, Bentham Publishers, Sharja, U.A.E. 66-77 (2009)
3. Varsha Thomas, Y. Murali Mohan, Manjula Bajpai and S.K. Bajpai, Synthesis of Metal Nanoparticles Using Hydrogel Networks, in “Recent Advances in Nanoscience and Nanotechnology”, Editors: S.K. Bajpai and Murali Mohan Yallapu, Bentham Publishers, Sharja, U.A.E. 78-84 (2009)
4. Varsha Thomas, Y. Murali Mohan, Grace Mary, M. Bajpai, S. K. Bajpai, Synthesis of Silver Nanomaterials and their Antibacterial Applications, In Encyclopedia of Nanoscience and Nanotechnology, Edited by H. S. Nalwa, American Scientific Publishers, Los Angeles Volume 24, 187-208 (2011).
5. Murali Mohan Yallapu, Meena Jaggi and Subhash C Chauhan, Design of Nanoparticle Mediated Targeted Drug Delivery: Ovarian Cancer, In Current Advances in Gynecological Oncology, 209-215 (2013)
6. **Yallapu MM***, Jaggi M, Chauhan SC*. Polyester particles for curcumin delivery, in “Handbook of Polyester Drug Delivery Systems” published by Pan Stanford Publishing Company, Chapter 19, pages 651-673 (2016)
7. Pluronic Nanotechnology for Overcoming Drug Resistance. Pallabita Chowdhury, Prashanth K.B. Nagesh, Santosh Kumar, Meena Jaggi, Subhash C. Chauhan, and **Murali M. Yallapu*** in Bioactivity of engineered nanoparticles (Editors: Bing Yan, Hongyu Zhou, and Jorge Gardea-Torresdey), Publisher Springer, 2017
8. Multifunctional magnetic nanoparticles for cancer treatment. Saini Setua, Meena Jaggi, **Murali M. Yallapu***, Subhash C. Chauhan* in Nanotechnologies in Preventive and Regenerative Medicine (Editor: Vuk Uskokovic), Publisher Elsevier, 2017

PEER-REVIEWED JOURNAL ARTICLES (Listed only International Publications):

Google Scholar Citations: 8895; i10-index-94; h-index-48

1. Shetty AB, Nagesh, PKB, Setua S, Hafeez BB, Jaggi M, **Yallapu MM***, Chauhan SC*. Novel paclitaxel nanoformulation impairs de novo lipid synthesis in pancreatic cancer cells and enhance gemcitabine efficacy, ACS Omega, 10.1021/acsomega.0c00793, April 10, 2020. As Soon As Published Article.
2. Chauhan SS, Shetty AB, Hatami E, Chowdhury P, **Yallapu MM***. Pectin-Tannic Acid Nano-Complexes Promote the Delivery and Bioactivity of Drugs in Pancreatic Cancer Cells. Pharmaceutics. 2020 Mar 22;12(3). pii: E285. doi:10.3390/pharmaceutics12030285. PubMed PMID: 32235765.
3. Gong Y, Chowdhury P, Nagesh PKB, Rahman MA, Zhi K, **Yallapu MM***, Kumar S*. Novel elvitegravir nanoformulation for drug delivery across the blood-brain barrier to achieve HIV-1 suppression in the CNS macrophages. Sci Rep. 2020 Mar 2;10(1):3835. doi: 10.1038/s41598-020-60684-1. PubMed PMID: 32123217; PubMed Central PMCID: PMC7052245.
4. Chauhan N, Kruse A, Newby H, Jaggi M, **Yallapu MM***, Chauhan SC*. Pluronic Polymer-Based Ormeloxifene Nanoformulations Induce Superior Anticancer Effects in Pancreatic Cancer Cells. ACS Omega. 2020 Jan 9;5(2):1147-1156. doi: 10.1021/acsomega.9b03382. eCollection 2020 Jan 21. PubMed PMID: 31984272; PubMed Central PMCID: PMC6977081.
5. Nagesh PKB, Chowdhury P, Hatami E, Jain S, Dan N, Kashyap VK, Chauhan SC, Jaggi M, **Yallapu MM***. Tannic acid inhibits lipid metabolism and induce ROS in prostate cancer cells. Sci Rep. 2020 Jan 22;10(1):980. doi: 10.1038/s41598-020-57932-9. PubMed PMID: 31969643; PubMed Central PMCID: PMC6976712.
6. Massey AE, Doxtater KA, **Yallapu MM***, Chauhan SC*. Biophysical changes caused by altered MUC13 expression in pancreatic cancer cells. Micron. 2020 Mar;130:102822. doi: 10.1016/j.micron.2019.102822. Epub 2020 Jan 3. PubMed PMID: 31927412; PubMed Central PMCID: PMC7014956.
7. Sikander M, Malik S, Khan S, Kumari S, Chauhan N, Khan P, Halaweish FT, Chauhan B, **Yallapu MM***, Jaggi M*, Chauhan SC*. Novel Mechanistic Insight into the Anticancer Activity of Cucurbitacin D against Pancreatic Cancer (Cuc D Attenuates Pancreatic Cancer). Cells. 2019 Dec 31;9(1). pii: E103. doi: 10.3390/cells9010103. PubMed PMID: 31906106; PubMed Central PMCID: PMC7017063.
8. Adhikari P, Nagesh PKB, Alharthi F, Chauhan SC, Jaggi M, **Yallapu MM***, Pradhan P*. Optical detection of the structural properties of tumor tissue generated by xenografting of drug-sensitive and drug-resistant cancer cells using partial wave spectroscopy (PWS). Biomed Opt Express. 2019 Nov 21;10(12):6422-6431. doi:

- 10.1364/BOE.10.006422. eCollection 2019 Dec 1. PubMed PMID: 31853408; PubMed Central PMCID: PMC6913405.
9. Kumari S, Khan S, Sekhri R, Mandil H, Behrman S, **Yallapu MM**, Chauhan SC*, Jaggi M*. Protein kinase D1 regulates metabolic switch in pancreatic cancer via modulation of mTORC1. *Br J Cancer*. 2020 Jan;122(1):121-131. doi: 10.1038/s41416-019-0629-9. Epub 2019 Dec 10. PubMed PMID: 31819177; PubMed Central PMCID: PMC6964700.
 10. Kashyap VK, Dan N, Chauhan N, Wang Q, Setua S, Nagesh PKB, Malik S, Batra V, **Yallapu MM**, Miller DD, Li W, Hafeez BB, Jaggi M, Chauhan SC*. VERU-111 suppresses tumor growth and metastatic phenotypes of cervical cancer cells through the activation of p53 signaling pathway. *Cancer Lett*. 2020 Feb 1;470:64-74. doi: 10.1016/j.canlet.2019.11.035. Epub 2019 Dec 3. PubMed PMID: 31809801.
 11. Samanta K, Setua S, Kumari S, Jaggi M, **Yallapu MM***, Chauhan SC*. Gemcitabine Combination Nano Therapies for Pancreatic Cancer. *Pharmaceutics*. 2019 Nov 4;11(11). pii: E574. doi: 10.3390/pharmaceutics11110574. Review. PubMed PMID: 31689930; PubMed Central PMCID: PMC6920852.
 12. Chauhan N, Maher DM, Hafeez BB, Mandil H, Singh MM, **Yallapu MM**, Jaggi M, Chauhan SC. Ormeloxifene nanotherapy for cervical cancer treatment. *Int J Nanomedicine*. 2019 Sep 3;14:7107-7121. doi: 10.2147/IJN.S200944. eCollection 2019. PubMed PMID: 31564868; PubMed Central PMCID: PMC6731961.
 13. Nagesh PKB, Chowdhury P, Hatami E, Kumari S, Kashyap VK, Tripathi MK, Wagh S, Meibohm B, Chauhan SC, Jaggi M, **Yallapu MM***. Cross-Linked Polyphenol-Based Drug Nano-Self-Assemblies Engineered to Blockade Prostate Cancer Senescence. *ACS Appl Mater Interfaces*. 2019 Oct 23;11(42):38537-38554. doi: 10.1021/acsami.9b14738. Epub 2019 Oct 8. PubMed PMID: 31553876.
 14. Chauhan N, Maher DM, **Yallapu MM**, B Hafeez B, Singh MM, Chauhan SC*, Jaggi M*. A triphenylethylene nonsteroidal SERM attenuates cervical cancer growth. *Sci Rep*. 2019 Jul 29;9(1):10917. doi: 10.1038/s41598-019-46680-0. PubMed PMID: 31358785; PubMed Central PMCID: PMC6662837.
 15. Gong Y, Chowdhury P, Nagesh PKB, Cory TJ, Dezfuli C, Kodidela S, Singh A, **Yallapu MM***, Kumar S*. Nanotechnology approaches for delivery of cytochrome P450 substrates in HIV treatment. *Expert Opin Drug Deliv*. 2019 Jul 24;1-14. doi: 10.1080/17425247.2019.1646725. [Epub ahead of print] PMID: 31328582
 16. Massey AE, Sikander M, Chauhan N, Kumari S, Setua S, Shetty AB, Mandil H, Kashyap VK, Khan S, Jaggi M, **Yallapu MM**, Hafeez BB, Chauhan SC. Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. *Nanomedicine*. 2019 Jun 4;20:102027. doi: 10.1016/j.nano.2019.102027. [Epub ahead of print] PMID: 31170509
 17. Khan S, Setua S, Kumari S, Dan N, Massey A, Hafeez BB, **Yallapu MM**, Stiles ZE, Alabkaa A, Yue J, Ganju A, Behrman S, Jaggi M, Chauhan SC*. Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. *Biomaterials*. 2019 Jul;208:83-97. doi: 10.1016/j.biomaterials.2019.04.005. Epub 2019 Apr 8. PMID: 30999154
 18. Sikander M, Malik S, Chauhan N, Khan P, Kumari S, Kashyap VK, Khan S, Ganju A, Halaweish FT, **Yallapu MM**, Jaggi M, Chauhan SC*. Cucurbitacin D Reprograms Glucose Metabolic Network in Prostate Cancer. *Cancers (Basel)*. 2019 Mar 14;11(3). pii: E364. doi: 10.3390/cancers11030364. PMID: 30875788
 19. Hatami E, Mu Y, Shields DN, Chauhan SC, Kumar S, Cory TJ, **Yallapu MM***. Mannose-decorated hybrid nanoparticles for enhanced macrophage targeting. *Biochem Biophys Rep*. 2019 Jan 25;17:197-207. doi: 10.1016/j.bbrep.2019.01.007. eCollection 2019 Mar. PMID: 30723809
 20. Gong Y, Haque S, Chowdhury P, Cory TJ, Kodidela S, **Yallapu MM**, Norwood JM, Kumar S. Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment. *Expert Opin Drug Metab Toxicol*. 2019 May;15(5):417-427. doi: 10.1080/17425255.2019.1604685. Epub 2019 Apr 20. PMID: 30951643.
 21. Chowdhury P, Nagesh PKB, Hatami E, Wagh S, Dan N, Tripathi MK, Khan S, Hafeez BB, Meibohm B, Chauhan SC, Jaggi M, **Yallapu MM***. Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells. *J Colloid Interface Sci*. 2018 Sep 22;535:133-148. doi: 10.1016/j.jcis.2018.09.072. [Epub ahead of print] PubMed PMID: 30292104.
 22. Tripathi MK, Zacheaus C, Doxtater K, Keramatnia F, Gao C, **Yallapu MM**, Jaggi M, Chauhan SC. Z Probe, An Efficient Tool for Characterizing Long Non-Coding RNA in FFPE Tissues. *Noncoding RNA*. 2018 Sep 5;4(3). pii: E20. doi: 10.3390/ncrna4030020. PubMed PMID: 30189670; PubMed Central PMCID: PMC6162476.
 23. Varaprasad K, **Yallapu MM**, Núñez D, Oyarzún P, López M, Jayaramudu T, Karthikeyan C., Generation of engineered core-shell antibiotic nanoparticles. *RSC Adv*. 2019 Mar 14;9(15):8326-8332. doi: 10.1039/c9ra00536f. Epub 2019 Mar 13. PMID: 31131098 Free PMC Article

24. Nagesh PKB, Chowdhury P, Hatami E, Boya VKN, Kashyap VK, Khan S, Hafeez BB, Chauhan SC, Jaggi M, **Yallapu MM***miRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy. *Cancers* (Basel). 2018 Aug 25;10(9). pii: E289. doi: 10.3390/cancers10090289. PubMed PMID: 30149628; PubMed Central PMCID: PMC6162422.
25. Hatami E, Nagesh PKB, Chowdhury P, Chauhan SC, Jaggi M, Samarasinghe AE, **Yallapu MM***. Tannic Acid-Lung Fluid Assemblies Promote Interaction and Delivery of Drugs to Lung Cancer Cells. *Pharmaceutics*. 2018 Aug 1;10(3). pii: E111. doi: 10.3390/pharmaceutics10030111. PubMed PMID: 30071698; PubMed Central PMCID: PMC6161105.
26. Nagesh PKB, Hatami E, Chowdhury P, Kashyap VK, Khan S, Hafeez BB, Chauhan SC, Jaggi M, **Yallapu MM***. Tannic Acid Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in Prostate Cancer. *Cancers* (Basel). 2018 Mar 7;10(3). pii: E68. doi: 10.3390/cancers10030068. PubMed PMID: 29518944; PubMed Central PMCID: PMC5876643.
27. Pallabita Chowdhury, Prashanth K.B. Nagesh, Sheema Khan, Bilal B. Hafeez, Subhash C. Chauhan, Meena Jaggi, **Murali M. Yallapu***, Development of polyvinylpyrrolidone/paclitaxel self-assemblies for breast cancer, *Acta Pharmaceutica Sinica B*, 2018, 8, 602-614.
28. Varaprasad K, Nunez D, **Yallapu MM**, Jayaramudu T, Elgueta E, Oyarzun P. Nano-hydroxyapatite polymeric hydrogels for dye removal. *RSC Adv*. 2018 May 16;8(32):18118-18127. doi: 10.1039/c8ra01887a. Epub 2018 May 17. PubMed PMID: 29904603; PubMed Central PMCID: PMC5961604.
29. Kumar BNP, Puvvada N, Rajput S, Sarkar S, Mahto MK, **Yallapu MM**, Pathak A, Emdad L, Das SK, Reis RL, Kundu SC, Fisher PB, Mandal M. Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica-Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer. *Mol Pharm*. 2018 Jul 2;15(7):2698-2713. doi: 10.1021/acs.molpharmaceut.8b00218. Epub 2018 May 30. PubMed PMID: 29787277.
30. Tripathi MK, Doxtater K, Keramatnia F, Zacheaus C, **Yallapu MM**, Jaggi M, Chauhan SC. Role of lncRNAs in ovarian cancer: defining new biomarkers for therapeutic purposes. *Drug Discov Today*. 2018 Apr 23. pii: 1359-6446(18)30071-0. doi: 10.1016/j.drudis.2018.04.010. [Epub ahead of print] Review. PubMed PMID:29698834.
31. Dan N, Setua S, Kashyap VK, Khan S, Jaggi M, Yallapu MM, Chauhan SC. Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications. *Pharmaceutics* (Basel). 2018 Apr 9;11(2). pii: E32. doi: 10.3390/ph11020032. Review. PubMed PMID: 29642542.
32. Almbadi HM, Nagesh PKB, Sahay P, Bhandari S, Eckstein EC, Jaggi M, Chauhan SC, **Yallapu MM**, Pradhan P. Optical study of chemotherapy efficiency in cancer treatment via intracellular structural disorder analysis using partial wave spectroscopy. *J Biophotonics*. 2018 Jun 5:e201800056. doi: 10.1002/jbio.201800056. [Epub ahead of print] PubMed PMID: 29869394.
33. Gong Y, Chowdhury P, Midde NM, Rahman MA, **Yallapu MM**, Kumar S. Novel elvitegravir nanoformulation approach to suppress the viral load in HIV-infected macrophages. *Biochem Biophys Rep*. 2017 Nov 15;12:214-219. doi: 10.1016/j.bbrep.2017.10.005. eCollection 2017 Dec. PubMed PMID: 29214223; PubMed Central PMCID: PMC5704044.
34. Dan N, Setua S, Kashyap VK, Khan S, Jaggi M, **Yallapu MM***, Chauhan SC*. Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications. *Pharmaceutics* (Basel). 2018 Apr 9;11(2). pii: E32. doi: 10.3390/ph11020032. Review. PubMed PMID: 29642542.
35. Tripathi MK*, Doxtater K, Keramatnia F, Zacheaus C, **Yallapu MM**, Jaggi M, Chauhan SC*. Role of lncRNAs in ovarian cancer: defining new biomarkers for therapeutic purposes. *Drug Discov Today*. 2018 Apr 23. pii: S1359-6446(18)30071-0. doi: 10.1016/j.drudis.2018.04.010. [Epub ahead of print] Review. PubMed PMID: 29698834.
36. Kumari S, Khan S, Gupta SC, Kashyap VK, **Yallapu MM**, Chauhan SC*, Jaggi M*. MUC13 contributes to rewiring of glucose metabolism in pancreatic cancer. *Oncogenesis*. 2018 Feb 22;7(2):19. doi: 10.1038/s41389-018-0031-0. PubMed PMID: 29467405; PubMed Central PMCID: PMC5833644.
37. Ganju A, Chauhan SC, Hafeez BB, Doxtater K, Tripathi MK, Zafar N, **Yallapu MM**, Kumar R, Jaggi M*. Protein kinase D1 regulates subcellular localisation and metastatic function of metastasis-associated protein 1. *Br J Cancer*. 2018 Feb 20;118(4):587-599. doi: 10.1038/bjc.2017.431. Epub 2018 Feb 20. PubMed PMID: 29465084; PubMed Central PMCID: PMC5830591.
38. Khan S, Zafar N, Khan SS, Setua S, Behrman SW, Stiles ZE, **Yallapu MM**, Sahay P, Ghimire H, Ise T, Nagata S, Wang L, Wan JY, Pradhan P, Jaggi M, Chauhan SC*. Clinical significance of MUC13 in pancreatic ductal adenocarcinoma. *HPB* (Oxford). 2018 Jan 15. pii: S1365-182X(17)31184-X. doi: 10.1016/j.hpb.2017.12.003. [Epub ahead of print] PubMed PMID: 29352660.

39. Sahay P, Ganju A, Almadadi HM, Ghimire HM, **Yallapu MM**, Skalli O, Jaggi M, Chauhan SC, Pradhan P*. Quantification of photonic localization properties of targeted nuclear mass density variations: Application in cancer-stage detection. *J Biophotonics*. 2017 Dec 9. doi: 10.1002/jbio.201700257. [Epub ahead of print] PubMed PMID: 29222925.
40. Kumar S, Sinha N, Gerth KA, Rahman MA, **Yallapu MM**, Midde NM. Specific packaging and circulation of cytochromes P450, especially 2E1 isozyme, in human plasma exosomes and their implications in cellular communications. *Biochem Biophys Res Commun*. 2017 Sep 23;491(3):675-680. doi: 10.1016/j.bbrc.2017.07.145. Epub 2017 Jul 26. PubMed PMID: 28756226; PubMed Central PMCID: PMC5901973.
41. Varaprasad K, Raghavendra GM, Jayaramudu T, **Yallapu MM**, Sadiku R. A mini review on hydrogels classification and recent developments in miscellaneous applications. *Mater Sci Eng C Mater Biol Appl*. 2017 Oct 1;79:958-971. doi: 10.1016/j.msec.2017.05.096. Epub 2017 May 15. Review. PubMed PMID: 28629101.
42. Magnetic nanoformulations for prostate cancer, Chowdhury P, Roberts AM, Khan S, Hafeez BB, Jaggi M, Chauhan SC, and **Yallapu MM***, *Drug Discovery Today*, 2017 (Accepted)
43. Boya VN, Lovett R, Setua S, Gandhi V, Nagesh PK, Khan S, Jaggi M, **Yallapu MM***, **Chauhan SC***. Probing mucin interaction behavior of magnetic nanoparticles. *J Colloid Interface Sci*. 488:258-268, 2017.
44. Ganju A, Khan S, Hafeez BB, Behrman SW, **Yallapu MM***, Chauhan SC*, Jaggi M*. miRNA nanotherapeutics for cancer. *Drug Discov Today*. 22(2):424-432, 2017.
45. Yadav HM, Thorat ND, **Yallapu MM**, Tofail SAM, Kim JS*, Functional TiO₂ nanocoral architecture for light-activated cancer chemotherapy, *Journal of Materials Chemistry B* 5 (7), 1461-1470, 2017.
46. Karuri AR, Kashyap VK, **Yallapu MM**, Zafar N, Kedia SK, Jaggi M, Chauhan SC*. Disparity in rates of HPV infection and cervical cancer in underserved US populations. *Front Biosci (Schol Ed)*. 2017 Jun 1;9:254-269.
47. Sikander M, Hafeez BB, Malik S, Alsayari A, Halaweish FT, **Yallapu MM**, Chauhan SC*, Jaggi M. Cucurbitacin D exhibits potent anti-cancer activity in cervical cancer. *Sci Rep*. 8;6:36594, 2017.
48. Setua S, Khan S, **Yallapu MM**, Behrman SW, Sikander M, Khan SS, Jaggi M, Chauhan SC. Restitution of Tumor Suppressor MicroRNA-145 Using Magnetic Nanoformulation for Pancreatic Cancer Therapy. *J Gastrointest Surg*. 21(1):94-105, 2017.
49. Khan S, Sikander M, Ebeling MC, Ganju A, Kumari S, **Yallapu MM**, Hafeez BB, Ise T, Nagata S, Zafar N, Behrman SW, Wan JY, Ghimire HM, Sahay P, Pradhan P, Chauhan SC, Jaggi M. MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression. *Oncogene*. 36(4):491-500, 2017.
50. Nagesh PK, Johnson NR, Boya VK, Chowdhury P, Othman SF, Khalilzad-Sharghi V, Hafeez BB, Ganju A, Khan S, Behrman SW, Zafar N, Chauhan SC, Jaggi M, **Yallapu MM***. PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. *Colloids Surf B Biointerfaces*. 144, 8-20, 2016
51. Zaman MS, Chauhan N, **Yallapu MM**, Gara RK, Maher DM, Kumari S, Sikander M, Khan S, Zafar N, Jaggi M, Chauhan SC. Curcumin Nanoformulation for Cervical Cancer Treatment. *Sci Rep*. 2016 Feb 3;6:20051.
52. Rao P, **Yallapu MM**, Sari Y, Fisher PB, Kumar S. Designing Novel Nanoformulations Targeting Glutamate Transporter Excitatory Amino Acid Transporter 2: Implications in Treating Drug Addiction. *J Pers Nanomed*. 2015;1(1):3-9.
53. **Yallapu, MM***, Nagesh, PK, Jaggi, M, Chauhan, SC. Therapeutic Applications of Curcumin Nanoformulations. *AAPS J*, 17(6), 3-9, 2015.
54. Khan S, Chauhan N, **Yallapu MM**, Ebeling MC, Balakrishna S, Ellis RT, Thompson PA, Balabathula P, Behrman SW, Zafar N, Singh MM, Halaweish FT, Jaggi M, Chauhan SC*. Nanoparticle formulation of ormeloxifene for pancreatic cancer. **Biomaterials**. 2015, 53:731-43. PubMed PMID: 25890768; PubMed Central PMCID: PMC4405677.
55. Khan S, Ebeling MC, Chauhan N, Thompson PA, Gara RK, Ganju A, **Yallapu MM**, Behrman SW, Zhao H, Zafar N, Singh MM, Jaggi M, Chauhan SC*. Ormeloxifene Suppresses Desmoplasia and Enhances Sensitivity of Gemcitabine in Pancreatic Cancer. **Cancer Res**. 2015 Apr 3. pii: canres.2397.2014. [Epub ahead of print] PubMed PMID: 25840985.
56. **Yallapu MM***, Chauhan N, Othman SF, Khalilzad-Sharghi V, Ebeling MC, Khan S, Jaggi M, Chauhan SC*. Implications of protein corona on physico-chemical and biological properties of magnetic nanoparticles. **Biomaterials**. 2015, 46:1-12. PubMed PMID: 25678111.

57. Khan S, Ebeling MC, Zaman MS, Sikander M, Yallapu MM, Chauhan N, Yacoubian AM, Behrman SW, Zafar N, Kumar D, Thompson PA, Jaggi M, Chauhan SC. MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. **Oncotarget**. 2014, 5(17):7599-609. PubMed PMID: 25277192.
58. Gara RK, Kumari S, Ganju A, **Yallapu MM**, Jaggi M, Chauhan SC*. Slit/Robo pathway: a promising therapeutic target for cancer. **Drug Discov Today**. 2015, 20(1):156-64. PubMed PMID: 25245168.
59. **Yallapu MM**, Khan S, Maher DM, Ebeling MC, Sundram V, Chauhan N, Ganju A, Balakrishna S, Gupta BK, Zafar N, Jaggi M, Chauhan SC*. Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. **Biomaterials**. 2014 Oct;35(30):8635-48. PubMed PMID: 25028336.
60. **Yallapu MM***, Katti KS, Katti DR, Mishra SR, Khan S, Jaggi M, Chauhan SC*. The roles of cellular nanomechanics in cancer. **Med Res Rev**. 2015, 35(1):198-223. PubMed PMID: 25137233.
61. **Murali M Yallapu**, Mara C Ebleing, Sheema Khan, Vasudha Sundram, Neeraj Chauhan, Brij K Gupta, Susan E Puumala, Meena Jaggi, and Subhash C Chauhan, Novel Curcumin Loaded Magnetic Nanoparticles for Pancreatic Cancer Treatment, *Molecular Cancer Therapeutics*, 2(8):1471-80 (2013) PMID 23704793
62. **Murali M Yallapu**, Meena Jaggi, Subhash C Chauhan, Plasma Proteins Interaction with Curcumin nanoparticles: Implications in Cancer Therapeutics, *Current Drug Metabolism*, 14(4):504-15 (2013) PMID 23566382
63. **Murali M Yallapu**, Meena Jaggi, Subhash C Chauhan, Curcumin Nanomedicine: A Road to Cancer Therapeutics, *Current Pharmaceutical Design*. 19, 1994-2010 (2013) PMID: 23116309
64. S.K. Bajpai, V. Pathak, Bhawna Soni, **Y.M. Mohan**, CNWs loaded poly(SA) hydrogels: Effect of high concentration of CNWs on water uptake and mechanical properties, *Carbohydrate Polymers*, 2014; 106: 351-358
65. **Y. Murali Mohan**, V. Raghunath, S. Sivaram, and D. Baskaran, Reactive Polymers Bearing Styrene Pendants through Selective Anionic Polymerization of 4-Vinylbenzyl Methacrylate, *Macromolecules*, 45, 3387-3393 (2012)
66. **Murali M Yallapu**, Shadi F Othman, Evan T. Curtis, Chauhan N, Nichole A Bauer, Deepak Kumar, Jaggi M, Chauhan SC, Curcumin loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications, *International Journal of Nanomedicine*, 7, 1761-1779 (2012) PMID: 22619526
67. **Murali M Yallapu**, Meena Jaggi, Subhash C Chauhan, Curcumin nanoformulations: A future nanomedicine for cancer, *Drug Discovery Today*, 17(1-2), 71-80 (2012) PMID: 21959306
68. **Murali M Yallapu**, Mitch R Dobberpuhl, Diane M Maher, Meena Jaggi, and Subhash C Chauhan, Design of curcumin loaded cellulose nanoparticles for prostate cancer, *Current Drug Metabolism*, 13(1), 120-128 (2012) PMID: 2189291
69. **Murali M Yallapu**, Ebeling MC, Chauhan N, Jaggi M, Chauhan SC, Interaction of Curcumin nanoformulations with human plasma proteins and erythrocytes, *International Journal of Nanomedicine*, 6, 2779-2780 (2011) PMID 22128249
70. Narayana Reddy, **Murali Mohan Yallapu**, Vara Prasad Kokkarachedu, Ravindra Sakey, Vimala Kanikireddy, Joy Pattayil, Konduru Mohana Raju, Preparation and characterization of magnetic nanoparticles embedded in hydrogels for protein purification and metal extraction, *Journal of Polymer Research*, 18, 2285-2294 (2011)
71. **Murali M Yallapu**, Mara Ebeling, Neeraj Chauhan, Meena Jaggi, Subhash C Chauhan, Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes, *International Journal of Nanomedicine*, 6, 2779-2790 (2011) PMID: 22128249
72. **Murali M Yallapu**, Meena Jaggi, Subhash C Chauhan, Design and engineering of nanogels for cancer treatment, *Drug Discovery Today*, 16, 457-463 (2011) PMID:21414419
73. **Murali M. Yallapu**, Shadi F. Othman, Evan T. Curtis, Brij K. Gupta, Meena Jaggi, Subhash C. Chauhan, Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy, *Biomaterials*, 32, 1890-1905 (2011). PMID: 21167595
74. N. Narayana Reddy, **Y. Murali Mohan**, K. Varaprasad, S. Ravindra, P.A. Joy, K. Mohana Raju, Magnetic and electric responsive hydrogel-magnetic nanocomposites for drug-delivery applications, *Journal of Applied Polymer Science*, 122, 1364-1375 (2011)
75. K. Varaprasad, **Y. Murali Mohan**, K. Vimala, K. Mohana Raju, Synthesis and characterization of hydrogel-silver nanoparticles-curcumin composites for wound dressing and antibacterial application, *Journal of Applied Polymer Science*, 121, 784-796(2011)
76. Sangphil Park, Murthy PSK, Saemi Park, **Y. Murali Mohan**, Wong-Gun Koh, Preparation of silver nanoparticles-containing semi-interpenetrating network hydrogels composed of pluronic and poly(acrylamide) with antibacterial property, *J Industr Eng Chem*, 17, 293-297 (2011)

77. **Murali Mohan Yallapu**, Susan Foy, Tapan Jain, Vinod Labhasetwar, PEG-functinoalized Magnetic Nanoparticles for Drug Delivery and Magnetic Resonance Imaging Applications, *Phamaceutical Research*, 27, 2283-2295 (2010). PMID: 20845067
78. **Murali Mohan Yallapu**, Meena Jaggi, Subhash C Chauhan, Scope of Nanotechnology inOvarian Cancer, *Journal of Ovarian Research*, 3:19 (2010). PMID: 20691083
79. **Murali M Yallapu**, Meena Jaggi, Subhash C Chauhan, Fabrication of curcuminencapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells, *Journal of colloid and interface science*, 351, 19-29 (2010). PMID: 20627257
80. **Murali Mohan Yallapu**, Meena Jaggi and Subhash C Chauhan, Poly(beta-cyclodextrin)/Curcumin Self-Assembly: A Novel Approach to Improve Curcumin Delivery and its Therapeutic Efficacy in Prostate Cancer Cells. *Macromoleculare Bioscience*, 10, 1141-1151 (2010). PMID: 20572274
81. **Murali Mohan Yallapu**, Meena Jaggi and Subhash C Chauhan, beta-Cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells. *Colloids Surf B Biointerfaces*, 79, 113-25 (2010) PMID: 20456930
82. **Murali M Yallapu**, Diane M Maher, Vasudha Sundram, Maria C Bell, Meena Jaggi andSubhash C Chauhan, Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth, *Journal of OvarianResearch*, 3:11 (2010). PMID: 20429876
83. K. Vimala, **Y. Murali Mohan**, K. Samba sivudu, K. Varaprasad, S. Ravindra, N. Narayana Reddy, Y. Padma, B. Sreedhar, K. MohanaRaju, Fabrication of porous chitosan films impregnated with silver nanoparticles: A facile approach for superior antibacterial application, *Colloids and Surfaces B: Biointerfaces*, 76, 248-258 (2010) PMID: 19945827
84. **Y. Murali Mohan**, K. Vimala, Varsha Thomas, K. Varaprasad, B. Sreedhar, S.K. Bajpai, K. Mohana Raju, Controlling of Silver Nanoparticles Structure by Hydrogel Networks, *J. Colloid. Interf. Sci.*, 342, 73-82 (2010). PMID: 19883919
85. N. Narayana Reddy, **Y. Murali Mohan**, K. Varaprasad, S. Ravindra, K. Vimala, K. Mohana Raju, Surface treatment of plasticized poly(vinyl chloride) to prevent plasticizer migration, *Journal of Applied Polymer Science*, 115, **1589-1597**, (2010)
86. Varsha Thomas, **Murali Mohan Yallapu**, B. Sreedhar, S. K. Bajpai, Fabrication, Characterization of Chitosan/Nanosilver Film and Its Potential Antibacterial Application, *Journal of Biomaterials Science, Polymer Edition*, 20(14), 2129-2144 (2009). PMID:19874682
87. Maram K. Reddy, Jaspreet Vasir, S.K. Sahoo, Tapan K. Jain, **Y. Murali Mohan**, V.Labhasetwar, Inhibition of apoptosis via localized delivery of rapamycin-loaded nanoparticles prevents neointimal hyperplasia and re-endothelialize injured artery, *Circulation: Cardiovascular Interventions*, 1(3), 209-216 (2008). PMID: 20031680
88. Varsha Thomas, **Murali Mohan Yallapu**, B. Sreedhar, S. K. Bajpai, Breathing- in/breathing-out approach to preparing nanosilver-loaded hydrogels: Highly efficientantibacterial nanocomposites, *Journal of Applied Polymer Science*, 111, 934-944 (2009).
89. K. Vimala, K. Samba Sivudu, **Y. Murali Mohan**, B. Sreedhar, K. Mohana Raju, Controlled silver nanoparticles synthesis in semi-hydrogel networks of poly(acrylamide) and Carbohydrates: A rational methodology for antibacterial application. *CarbohydratePolymers*, 75, 463-471 (2009)
90. Ravindra; **Y. Murali Mohan**; K. Varaprasad; N. Narayana Reddy; K. Vimala; K. Mohana Raju, Surfactant-Modified Poly(acrylamide-co-acrylamido propane sulphonic acid) Hydrogels, *International Journal of Polymeric Materials*, 58, 278 – 296 (2009)
91. **Murali Mohan Yallapu**, Jaspreet K. Vasir, Tapan Jain, Sivakumar Vijayaraghavalu, andVinod Labhasetwar, Rapamycin-Loaded Poly(N-Isopropylacrylamide)-Based Nanogelsin Vascular Smooth Muscle Cells, *Journal of Biomedical Nanotechnology*, 4, 16-24 (2008)
92. K. Samba Sivudu, N. Mallikarjuna Reddy, M. Nagendra Prasad, K. Mohana Raju, **Y. Murali Mohan**, J.S. Yadav, G. Sabitha, D. Shailaja, Highly efficient and reusable hydrogel-supported nano-palladium catalyst: Evaluation for Suzuki–Miyaura reaction in water, *Journal of Molecular Catalysis A: Chemical*, 295, 10-17 (2008)
93. Mini Namdeo, Sutanjay Saxena, Rasika Tankhiwale, M. Bajpai, **Y.M. Mohan** and S. K.Bajpai, Magentic Nanoparticles for Drug Delivery Applications, *J. Nanosci. Nanotech. J. Nanosci. Nanotechnol.* 8, 3247–3271 (2008). PMID: 19051873
94. Varsha Thomas, Mini Namdeo, **Y. Murali Mohan**, S.K. Bajpai, M. Bajpai, Review on Polymer, Hydrogel and Microgel Metal Nanocomposites: A Facile Nanotechnological Approach, *J. Macromol. Sci. Part A. Pure Appl. Chem.*, 45, 107-119 (2008)

95. P.S.K. Murthy, **Y. Murali Mohan**, K. Varaprasad, B. Sreedhar and K. Mohana Raju, First successful design of semi-IPN hydrogel–silver nanocomposites: A facile approach for antibacterial application, *J. Colloid. Interf. Sci.*, 318, 217-224 (2008). PMID: 18005980
96. Thomas, **Murali Mohan Yallapu**, B. Sreedhar and S.K. Bajpai, A versatile strategy to fabricate hydrogel–silver nanocomposites and investigation of their antimicrobial activity, *J. Colloid. Interf. Sci.*, 315, 389-395 (2007). PMID: 1770738
97. S K Bajpai , **Y Murali Mohan** , M Bajpai , Rasika Tankhiwale , Varsha Thomas, Synthesis of polymer stabilized silver and gold nanostructures, *J Nanosci Nanotechnol.* 7, 2994-3010 (2007). PMID: 18019128
98. **Y. Murali Mohan**, T. Premkumar, D. K. Joseph, and Kurt E. Geckeler, Stimuli-Responsive Poly(N-Isopropylacrylamide-co-Sodium Acrylate) Hydrogels : A Swelling Study in Surfactant and Polymer Solutions, Revised to Reactive and Functional Polymers, 67, 844-858 (2007)
99. **Y. Murali Mohan**, K. E. Geckeler, Polyampholytic hydrogels: Poly(N-isopropylacrylamide)-based stimuli-responsive networks with poly(ethyleneimine), Reactive and Functional Polymers, 67, 144-155 (2007)
100. **Y. Murali Mohan**, K. Mohana Raju, K. Sambasivudu, S. Singh, and B. Sreedhar, Preparation of acacia-stabilized silver nanoparticles: A green approach, *Journal of Applied Polymer Science*, 106, 3375-3381 (2007)
101. **Y. M. Mohan**, D. K. Joseph, K. E. Geckeler, Poly(N-isopropylacrylamide-co-sodium acrylate) Hydrogels: Interactions with Surfactants, *Journal of Applied Polymer Science*, 103, 3423–3430 (2007)
102. **Y Murali Mohan**, Joseph P Dickson, Kurt E Geckeler, Swelling and diffusion characteristics of novel semi-interpenetrating network hydrogels composed of poly[acrylamide]-co-(sodium acrylate) and poly[(vinylsulfonic acid), sodium salt], *Polymer International*, 56, 175-185 (2007)
103. **Y. Murali Mohan**, Kyungjae Lee, Thathan Premkumar, Kurt E. Geckeler, Hydrogel networks as nanoreactors: A novel approach to silver nanoparticles for antibacterial applications, *Polymer*, 48, 158-164 (2006)
104. **Y. Murali Mohan**, Thathan Premkumar, Kyungjae Lee, Kurt E. Geckeler, Fabrication of Silver Nanoparticles in Hydrogel Networks, *Macromolecular Rapid Communications* 27, 1346-1354 (2006)
105. **Y. Murali Mohan**, P.S. Keshava Murthy and K. Mohana Raju. Preparation and Swelling Behaviour of Macroporous Poly(acrylamide-co-sodium methacrylate) Superabsorbent Hydrogels, *Journal of Applied Polymer Science*, 101, 3202-3214 (2006).
106. **Y. Murali Mohan**, Y. Mani, and K. Mohana Raju. Synthesis of azido polymers as potential energetic propellant binders, *Designed Monomers and Polymers*, 9, 201-236 (2006).
107. **Y. Murali Mohan**, P.S. Keshava Murthy, J. Sreeramulu and K. Mohana Raju, Semi-IPNs of Starch and Poly(acrylamide-co-sodium methacrylate): Preparation, Swelling and Diffusion Characteristics Evaluation, *Reactive and Functional Polymers* 66, 1482–1493 (2006)
108. **Y. Murali Mohan**, P.S. Keshava Murthy, B. Sreedhar and K. Mohana Raju. Synthesis and Swelling Behaviour of Acrylamide-Potassium Methacrylate Superabsorbent Copolymers, *International Journal of Polymeric Materials*, 55, 1-23 (2006)
109. **Y. Murali Mohan**, P.S. Keshava Murthy, B. Sreedhar and K. Mohana Raju. Swelling characteristics and Thermal Studies of pH Sensitive Poly(AAm-co-CMA) Superabsorbent Copolymers, *Journal of Applied Polymer Science*, 102, 1-12 (2006)
110. **Y. Murali Mohan**, K. Sudhakar, P.S. Keshava Murthy and K. Mohana Raju. Influence of Crosslinkers on Properties of Chemically Crosslinked Poly(acrylamide-co-maleic acid) Hydrogels, *International Journal of Polymeric Materials*, 55, 513 (2006)
111. **Y. Murali Mohan** and K. Mohana Raju. Synthesis and Characterization of GAP-THF Copolymers, *International Journal of Polymeric Materials*, 55, 217-231 (2006)
112. K. Mohana Raju, **Y. Murali Mohan**, P.S. Keshava Murthy, and G. Nagarjuna. Swelling Properties of Crosslinked poly(Acrylamide-Sodium Methacrylate) Superabsorbent Copolymers, *Macromolecules: An Indian Journal*, 1, 6 (2006)
113. **Y. Murali Mohan**, B. Sreedhar and K. Mohana Raju. Synthesis and Characterization of Glycidyl azide Polymer With Improved Azide Content, *International Journal of Polymeric Materials*, 55, 441 (2006)
114. K. Mohana Raju, **Y. Murali Mohan**, P.S. Keshava Murthy, B. Sreedhar. Acrylamide- Potassium Methacrylate Superabsorbent Copolymers: Synthesis, Swelling Kinetics And Effect Of Reaction Parameters On Swelling Behaviour, *Materials Science: An Indian Journal*, 2, 7 (2006)
115. **Y. Murali Mohan**, K. Sudhakar, P.S. K. Murthy, M. P. Raju, B.V. K. Naidu, and K. Mohana Raju. Effect of Crosslinkers on Swelling Characteristics and Phase separation of Crosslinked Poly(acrylamide-co-maleic acid) hydrogels, *International Journal of Polymeric Materials*, 55, 1-26 (2006)

116. **Y. Murali Mohan**, P.S. Keshava Murthy, K.M. Rao, J. Sreeramulu and K. Mohana Raju. Swelling Behaviour and Diffusion Studies of High Water Retainer Acrylamide/Potassium Methacrylate Hydrogels, *Journal of Applied Polymer Science*, 96, 1153-1164 (2005)
117. **Y. Murali Mohan**, P.S. Keshava Murthy and K. Mohana Raju, Synthesis, Characterization, Effect of Reaction Parameters on Swelling Properties of Acrylamide-Sodium Methacrylate Superabsorbent Copolymers, *Reactive and Functional Polymers*, 63, 11-26 (2005)
118. **Y. Murali Mohan** and K. Mohana Raju, Synthesis and Characterization of HTPB-GAP Crosslinked Copolymers, *Designed Monomers and Polymers*, 8 (2), 159-175 (2005)
119. **Y. Murali Mohan**, M. Padmanabha Raju and K. Mohana Raju. Synthesis and Characterization of GAP-PEG Copolymers, *International Journal of Polymeric Materials*, 54 (7), 651-666 (2005)
120. **Y. Murali Mohan**, P.S. Keshava Murthy, M. Mohan Reddy, M. P. Raju and K. Mohana Raju. Synthesis and Properties of Poly(AAm-KMA-MA) Hydrogels, *Journal of Polymeric Materials*, 22, 283-294 (2005)
121. **Y. Murali Mohan**, P.S. Keshava Murthy, and K. Mohana Raju. Miscibility Studies of Hydroxyl Terminated Polybutadiene and Glycidyl azide Polymer. *Journal of Pure and Applied Ultrasonics*, Vol. 27, 119 (2005)
122. **Y. Murali Mohan**, P.S. Keshava Murthy and K. Mohana Raju. Synthesis and Swelling Behaviour of Interpenetrating Network Polymers of Poly(vinyl alcohol) and poly(acrylamide-co-potassium methacrylate), *Designed Monomers and Polymers*, 8 (3), 187-202 (2005)
123. P. S. Keshava Murthy, **Y. Murali Mohan**, K.M. Rao, J. Sreeramulu and K. Mohana Raju. Effect of Potassium Methacrylate Content on Synthesis, Swelling and Diffusion Characteristics of Acrylamide / Potassium Methacrylate Hydrogels, *International Journal of Polymeric Materials*, 54, 899-916 (2005)
124. **Y. Murali Mohan**, P.S. K. Murthy, M. Mohan Reddy, and K. Mohana Raju. Synthesis, Swelling Properties of Crosslinked Poly(AAm-KMA-MA) Hydrogels, *J. Macromolecular Science Part A: Pure and Applied Chemistry*, A42, 1227-1245 (2005)
125. **Y. Murali Mohan**, P.S. Keshava Murthy and K. Mohana Raju. Swelling Behaviour of Semi-Interpenetrating Polymer Network Hydrogels Composed of Poly(vinyl alcohol) and Poly(acrylamide-co-sodium methacrylate), *Journal of Applied Polymer Science*, 98, 302-314 (2005)
126. K. Mohana Raju, M. Padmanabha Raju and **Y. Murali Mohan**. Synthesis and Swelling Behaviour of Superabsorbent Polymeric Materials, *International Journal of Polymeric Materials*, Vol.53, No.4, 419-429 (2004)
127. **Y. Murali Mohan**, M. Padmanabha Raju and K. Mohana Raju. Synthesis, Spectral and DSC Analysis of Glycidyl Azide Polymers Containing Different Initiating Diol Units, *Journal of Applied Polymer Science*, Vol. 93, 2157-2163 (2004)
128. K. Mohana Raju, M. Padmanabha Raju and **Y. Murali Mohan**, Synthesis of superabsorbent copolymers as water manageable materials, *Polymer International*, 52, 768-772 (2003)
129. K. Mohana Raju, M. Padmanabha Raju and **Y. Murali Mohan**. Synthesis and water absorbency of crosslinked superabsorbent polymers, *Journal of Applied Polymer Science* 85, 1795-1801 (2002)

RECENT PRESENTATIONS (Listed since 2009)

1. W1230-11-73 - Novel Elvitegravir Nanoformulation for Drug Delivery Across the Blood-Brain Barrier to Yuqing Gong, Pallabita Chowdhury, Prashanth Nagesh, Namita Sinha, Hao Chen, Mohammad Rahman, Murali Yallapu, Santosh Kumar, Wed, Nov 6 12:30 PM – 1:30 PM, AAPS, 2019, Nov 3-6, San Antonio, TX
2. M1530-10-68 - Chemo-natural Combination for Non-small Cell Lung Cancer Treatment: Combination of Gemcitabine and Gambogic Acid, Hatami E, Nagesh Bhusetty, Chowdhury P, Shetty A, Khan S, Chauhan S, Jaggi M, Yallapu MM. Wed, Mon, Nov 4 3:30 PM – 4:30 PM, AAPS, 2019, Nov 3-6, San Antonio, TX
3. NOVEL TANNIC ACID SELF-ASSEMBLIES INHIBITS THERAPY INDUCED SENESCENCE IN PROSTATE CANCER
4. Prashanth K.B. Nagesh, Pallabita Chowdhury, Elham Hatami, Sonam Kumari, Santosh Wagh, Vivek Kumar Kashyap, Bilal Hafeez, Sheema Khan, Manish Kumar Tripathi, Bernd Meibohm, Meena Jaggi, Subhash C. Chauhan, Murali M. Yallapu, 3rd Annual Research Symposium, Health Disparities: Community Engagement, Sep 11-12, 2019, Edinburg/McAllen, TX.
5. ORMELOXIFENE NANOTHERAPY FOR CERVICAL CANCER TREATMENT, Neeraj Chauhan, Diane M. Maher, Bilal B. Hafeez, Hassan Mandil, Man M. Singh, Meena Jaggi, Murali M. Yallapu, Subhash C. Chauhan, 3rd Annual Research Symposium, Health Disparities: Community Engagement, Sep 11-12, 2019, Edinburg/McAllen, TX.

6. NOVEL NANOPARTICLE FORMULATION OF VERU 111 FOR PANCREATIC CANCER THERAPY
7. Vivek K. Kashyap, Qinghui Wang, Neeraj Chauhan, Prashanth K.B. Nagesh, Murali M. Yallapu, Duane D. Miller, Wei Li, Bilal B. Hafeez, Meena Jaggi, Subhash C. Chauhan, 3rd Annual Research Symposium, Health Disparities: Community Engagement, Sep 11-12, 2019, Edinburg/McAllen, TX.
8. FERRICHROME: A NOVEL PRO-BIOTIC DERIVED AGENT FOR IMPROVING IMMUNOTHERAPY OF CANCER, Bilal Bin Hafeez, Mehdi Chaib, Sonam Kumari, Mohammed Sikander, Hassan Mandil, Liza Makowski, Ajeeth Kumar Pingili, Elham Hatami, Advait Shetty, Dan Nirnoy, Murali M. Yallapu, Meena Jaggi, Subhash C. Chauhan, 3rd Annual Research Symposium, Health Disparities: Community Engagement, Sep 11-12, 2019, Edinburg/McAllen, TX.
9. Re: Abstract # 6736 Alteration of tau-tubulin interactions renders chemo-sensitization and apoptosis in docetaxel resistant prostate cancer: A nanoparticle approach Session Type: Poster Session
Session Category: Experimental and Molecular Therapeutics
Session Title: Mechanisms of Sensitivity and Resistance to Targeted Therapy 1
Permanent Abstract Number: 3002 [Place this number on your poster]
10. #1255 Smartly ReDO ormeloxifene for cervical cancer growth inhibition Role: Co-Author
11. #7907 Stress regulated role of lncRNA Malat1 in colorectal cancer progression and metastasis Role: Co-Author
12. #6562 VERU-111 inhibits stem-like characteristics of pancreatic cancer cells through the modulation of Sonic hedgehog signaling Role: Co-Author
13. 679 / 2 - ABI-231: A novel small molecule suppresses tumor growth and metastatic phenotypes of cervical cancer cells via targeting HPV E6 and E7, V. K. Kashyap, B. B. Hafeez, Q. Wang, N. Chauhan, P. K. B. Nagesh, N. Dan, s. kumari, S. Malik, S. Setua, A. Ganju, M. M. Yallapu, D. D. Miller, W. Li, M. Jaggi, S. C. Chauhan, April 15, 2018, 1:00 PM - 5:00 PM, AACR 2018, Chicago, Illinois.
14. LB-011 / 11 - Novel nano-formulation of paclitaxel for pancreatic cancer therapy, B. B. Hafeez, A. E. Massey, V. K. Kashyap, M. Sikander, A. Shetty, M. Chaib, H. Mandil, M. Yallapu, M. Jaggi, S. C. Chauhan, April 15, 2018, 1:00 PM - 5:00 PM, AACR 2018, Chicago, Illinois.
15. 198 / 28 - MUC13 promotes pancreatic tumor-stromal interactions by influencing tumor microenvironment, S. S. Khan, K. Doxtater, S. Kumari, S. Setua, M. Sikander, S. Malik, M. M. Yallapu, S. W. Behrman, S. C. Chauhan, M. Jaggi, April 15, 2018, 1:00 PM - 5:00 PM, AACR 2018, Chicago, Illinois.
16. 1449 / 19 - Aberrant expression of protein kinase D1 influences metabolic reconditioning in pancreatic cancer, S. Kumari, S. Khan, M. M. Yallapu, S. C. Chauhan, M. Jaggi; April 16, 2018, 8:00 AM - 12:00 PM, AACR 2018, Chicago, Illinois.
17. 2110 / 25 - Therapeutic intervention for pancreatic cancer using autologous exosomes, S. Setua, S. Khan, M. Yallapu, S. Kumari, M. Jaggi, S. C. Chauhan; April 16, 2018, 1:00 PM - 5:00 PM, Chicago, Illinois.
18. 4657 / 20 - Docetaxel nanoformulation reverts drug resistance in prostate cancer, P. B. Nagesh, P. Chowdhury, E. Hatami, V. K. Kashyap, B. B. Hafeez, S. Khan, S. C. Chauhan, M. Jaggi, M. Yallapu, April 17, 2018, 1:00 PM - 5:00 PM, AACR 2018, Chicago, Illinois.
19. LB-400 / 28 - Tannic acid induces prostate cancer cell death via unfolded protein response (UPR) and modulation of CHOP, E. Hatami, P. Bhusetty Nagesh, P. Chowdhury, V. K. Kashyap, S. Khan, B. Hafeez, M. Jaggi, S. C. Chauhan, M. Yallapu; April 18, 2018, 8:00 AM - 12:00 PM, AACR 2018, Chicago, Illinois.
20. 5777 / 3 - Ormeloxifene augments the therapeutic response of enzalutamide via targeting androgen receptor splice variant 7, B. B. Hafeez, A. E. Massey, V. K. Kashyap, M. Sikander, A. Shetty, M. Chaib, H. Mandil, S. Malik, M. M. Yallapu, M. Jaggi, S. C. Chauhan; April 18, 2018, 8:00 AM - 12:00 PM AACR 2018, Chicago, Illinois.
21. 2934 / 14 - Cucurbitacin D enhances the therapeutic efficacy of docetaxel via targeting cancer stem cells and miR-145, M. Sikander, S. Malik, B. B. Hafeez, H. Mandil, F. T. Halaweish, M. Jaggi, S. C. Chauhan; April 16, 2018, 1:00 PM - 5:00 PM, AACR 2018, Chicago, Illinois.
22. 5178 / 10 - MUC13 is a novel molecular signature, for early detection and metastatic colorectal cancer, M. K. Tripathi, C. Zacheaus, K. Doxtater, Z. Stiles, F. Keramatnia, N. Zafar, M. Amin, M. Jaggi, S. Chauhan, April 18, 2018, 8:00 AM - 12:00 PM, AACR 2018, Chicago, Illinois.
23. 5138 / 19 - Comparative profiling for bacterial inhabitation in pancreatic ductal adenocarcinoma and matched adjacent normal tissues, S. S. Khan, P. Banerjee, S. Setua, D. Higgins, S. Kedia, Y. Jiang, M. Jaggi, S. Chauhan, April 18, 2018, 8:00 AM - 12:00 PM, AACR 2018, Chicago, Illinois.

24. M4065 - Docetaxel Loaded Magnetic Nanoparticles for Overcoming Drug Resistance in Prostate Cancer, Pallabita Chowdhury, Prashanth Kumar Nagesh, Elham Hatami, Sheema Khan, Subhash Chauhan, Meena Jaggi, Murali Yallapu, November 13 – Monday Time: 12:00 pm - 01:00 pm, AAPS 2017, San Diego.
25. W1020 - Physico-Chemical and Biological Interactions of Protein Corona of Human Lung Fluid with Tannic Acid Nanoformulation, Elham Hatami, Pallabita Chowdhury, Prashanth Bhusetty, Subhash Chauhan, Meena Jaggi, Murali Yallapu, 9:00 AM–10:00 AM Nov 15, 2017, AAPS 2017, San Diego.
26. M7068 - Self- Targeting Nanoparticles as a Potential Therapeutic Model for Targeting Cancer, Pallabita Chowdhury, Elham Hatami, Prashanth Kumar Nagesh, Sheema Khan, Subhash Chauhan, Meena Jaggi, Murali Yallapu, 3:00 PM–4:00 PM Nov 13, 2017, AAPS 2017, San Diego.
27. M5029 - Mir-145 Mediated TRAIL Sensitization In Pancreatic Cancer: Novel Combined Treatment Strategy, Saini Setua, Sheema Khan, Murali Yallapu, Stephen Behrman, Meena Jaggi, Subhash Chauhan, Poster Forum 2 - Monday - 01:00 pm, AAPS 2017, San Diego.
28. M7015 - Therapeutic Perspectives of Tannic Acid in Inducing ER Stress Mediated Unfolded Protein Response (UPR) in Prostate Cancer Cell Death, Prashanth Kumar Bhusetty Nagesh, Pallabita Chowdhury, Vivek Kumar Kashyap, Elham Hatami, Sheema Khan, Bilal Hafeez, Meena Jaggi, Subhash Chauhan, Murali Yallapu, Poster Forum 2 - Monday - 03:00 pm, AAPS 2017, San Diego.
29. W1128 - ABI-231: A novel microtubule inhibitor suppresses tumor growth and metastatic phenotypes of cervical cancer cells via targeting HPV E6 and E7, Vivek Kashyap, Bilal Hafeez, Qinghai Wang, Neeraj Chauhan, Prashanth K B Nagesh, Nirnoy Dan, Shabnam Malik, Saini Setua, Aditya Ganju, Murali Yallapu, Duane Miller, Wei Li, Meena Jaggi, Subhash Chauhan, Poster Forum 6 - Wednesday - 09:00 am, AAPS 2017, San Diego.
30. Efficacy of Different Chitosan Nanoparticle Combinations in Inhibiting Growth of Two Strains of: PR71Enterococcus Faecalis: PR71, M. James; P. Chowdhury; M. Yallapu; A. Lloyd; J. O'Dell; J. Babu; F. Garcia-Godoy; S. Chauhan; G. Huang; M. Marchesan, Journal of Endodontics. 44(3):e37, MAR 2018,
31. Partial wave spectroscopy based nanoscale structural disorder analysis for cancer diagnosis and treatment, Almbadi, Huda; Sahay, Peeyush; Nagesh, Prashanth K. B.; Yallapu, Murali M.; Jaggi, Meena; Chauhan, Subhash C.; Pradhan, Prabhakar, APS March Meeting 2017, abstract id. Y6.008
32. MUC13 PEPTIDE MODULATES TME OF PANCREATIC CANCER BY INDUCTION OF TAMs AND ACTIVATION OF CAFs: Mehdi Chaib, Advait Shetty, Andrew Massey, Sonam Kumari, Vivek Kashyab, Manish Tripathi, Bilal Hafeez, Meena Jaggi, Subhash C. Chauhan, April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA.
33. DOCETAXEL LOADED MAGNETIC NANOPARTICLES FOR OVERCOMING DRUG RESISTANCE IN PROSTATE CANCER: Pallabita Chowdhury, Prashanth K.B. Nagesh, Elham Hatami, Sheema Khan, Subhash C. Chauhan, Meena Jaggi, Murali M. Yallapu April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA.
34. TARGETED DRUG DELIVERY USING NOVEL ANTI_MUC12 CONJUGATED NANOPARTICLES FOR PANCREATIC CANCER: Nirnoy Dan, Saini Setua, Sheema Khan, Murali M. Yallapu, Meena Jaggi, Subhash C. Chauhan April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA.
35. TANNIC ACID INDUCES ENDOPLASMIC RETICULUM STRESS-MEDIATED APOPTOSIS IN PROSTATE CANCER: Elham Hatami, Prashanth K.B. Nagesh, Pallabita Chowdhury, Vivek Kashyab, Sheema Khan, Bilal Hafeez, Subhash C. Chauhan, Meena Jaggi, Murali M. Yallapu, April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA.
36. ABERRANT EXPRESSION OF PROTEIN KINASE D1 INFLUENCES METABOLIC RECONDITIONING IN PANCREATIC CANCER: Sonam Kumari, Sheema Khan, Murali M. Yallapu, Subhash C. Chauhan, Meena Jaggi April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA.
37. ASSESMENT OF PHYSICAL CHARACTERISTICS OF CANCER CELLS AND NANOPARTICLES BY ATOMIC FORCE MICROSCOPY: Andrew Massey, April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA.
38. TARGETING MUC12 TO IMPROVE SURVIVAL IN PATIENTS WHO SMOKE AND DRINK: Kamalika Samanta, Sheema Khan, Saini Setua, Sonam Kumari, Nirnoy Dan, Kyle Doxtater, Pragathi Reddy Gunnam,

Murali M. Yallapu, Meena Jaggi, Subhash C. Chauhan, April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA.

39. THERAPEUTIC INTERVENTION FOR PANCREATIC CANCER USING AUTOLOGOUS EXOSOMES: Saini Setua, Sheema Khan, Andrew Massey, Murali M. Yallapu, Meena Jaggi, Subhash C. Chauhan, April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA
40. Aditya Ganju, Bilal Bin Hafeez, Fathi Halaweish, Wei Li, Man Mohan Singh, **Murali Mohan Yallapu**, Subhash Chauhan, Meena Jaggi. Ormeloxifene, a novel pharmacological activator of PKD1 enhances docetaxel sensitivity in prostate cancer. Abstract Number 3862, Poster Session 19, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA.*
41. Sheema Khan, Mara C. Ebeling, Mohammad Sikander, Aditya Ganju, **Murali M. Yallapu**, Tomoko Ise, Satoshi Nagata, Stephen W. Behrman, Nadeem Zafar, Jim Y. Wan, Hemendra M. Ghimire, Peeyush Sahay, Prabhakar Pradhan, Meena Jaggi, Subhash C. Chauhan. MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression. Abstract Number 4592, Poster Session 8, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA.*
42. Mohammed Sikander, Bilal Bin Hafeez, Fathi T. Halaweish, **Murali M. Yallapu**, Meena Jaggi, Subhash C. Chauhan. Novel cucurbitacin analogue Cuc D exhibits potent anti-cancer activity in cervical cancer. Abstract Number 3081, Poster Session 19, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA.*
43. Vivek K. Kashyap, Sheema Khan, Mohammad Sikander, Diane M. Maher, Santosh Kumar, Namita Sinha, **Murali M. Yallapu**, Nadeem Zafar, Meena Jaggi, Subhash C. Chauhan. Comorbidity factors associated with human papillomavirus infectivity: Implications in cervical cancer health disparity. Abstract Number 1745, Poster Session 35, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA.*
44. Saini Setua, Sheema Khan, **Murali Mohan Yallapu**, Mohammed Sikander, Stephen W. Behrman, Meena Jaggi, Subhash C. Chauhan. Mir-145 based magnetic nanoformulation for pancreatic cancer therapy. Abstract Number 1071, Poster Session 6, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA.*
45. Prashanth Kumar Bhusetty Nagesh, Nia Johnson, Vijaya K.N. Boya, Pallabita Chowdhury, Aditya Ganju, Bilal Hafeez, Sheema Khan, Meena Jaggi, Subhash C. Chauhan, **Murali M. Yallapu**. PSMA antibody functionalized docetaxel-loaded magnetic nanoparticles for prostate cancer therapy. Abstract Number 1312, Poster Session 19, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA.*
46. Vijayakumar N. Boya, Renn Lovett, Saini Satua, Vaibhav Gandhi, Prashanth K.B. Nagesh, **Meena Jaggi**, Subhash C. Chauhan, **Murali M. Yallapu**. Mucopenetrating magnetic nanoparticles for drug delivery. Abstract Number 2197, Poster Session 20, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA.*
47. Bilal B. Hafeez, Vivek K. Kashyap, Vijayakumar N. Boya, Aditya Ganju, Mohammad Sikander, **Murali M. Yallapu**, Meena Jaggi, Subhash C. Chauhan. Novel nanoparticle formulation of Plumbagin for pancreatic cancer treatment. Abstract Number 2208, Poster Session 20, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA.*
48. Saini Setua, Stephen Behrman, Sheema Khan, **Murali M. Yallapu**, Meena Jaggi, Subhash C. Chauhan. Restitution of tumor suppressor miR-145 using magnetic nanoparticles inhibits pancreatic cancer. 50th Annual Pancreas Club Meeting May 20-21, 2016, the Hyatt Regency Mission Bay, San Diego California
49. Saini Setua, Stephen Behrman, Sheema Khan, **Murali M. Yallapu**, Meena Jaggi, Subhash C. Chauhan. Restitution of tumor suppressor miR-145 using magnetic nanoparticles inhibits pancreatic cancer. Digestive Disease Week (DDW), May 21-24, 2016, Convention Center, San Diego, California
50. Saini Setua, Sheema Khan, **Murali M. Yallapu**, Mohammed Sikander, Meena Jaggi, Subhash C. Chauhan. Restitution of tumor suppressor miR-145 using magnetic nanoparticles inhibits pancreatic cancer. 30 poster session, *Graduate Research Day 2015 (April 10), University of Tennessee Health Sciences Center, Memphis, TN.*
51. Sheema Khan, **Murali M. Yallapu**, Sonam Kumari, Aditya Ganju, Swathi Balakrishna, Stephen W. Behrman, Nadeem Zafar, Meena Jaggi, Subhash C. Chauhan. Attenuation of Pancreatic Cancer Stemness and Growth by a Novel Magnetic Nanoparticle Formulation. *2014 Poster session, UTHSC PhDA Postdoc Research Day Meeting (Dec 10, 2014), Memphis, TN.*
52. Best Poster Presentation Award to Sheema Khan, 2014 *UTHSC PhDA Postdoc Research Day Meeting*: Sheema Khan, **Murali M. Yallapu**, Sonam Kumari, Aditya Ganju, Swathi Balakrishna, Stephen W. Behrman, Nadeem

- Zafar, Meena Jaggi, Subhash C. Chauhan. Attenuation of Pancreatic Cancer Stemness and Growth by a Novel Magnetic Nanoparticle Formulation. *2014 PhDA Meeting Poster session, UTHSC Postdoc Research Day (Dec 10, 2014), Memphis, TN.*
53. UTHSC PhDA Winter Travel Award to Sheema Khan, 2014. Sheema Khan, **Murali M. Yallapu**, Sonam Kumari, Aditya Ganju, Swathi Balakrishna, Stephen W. Behrman, Nadeem Zafar, Meena Jaggi, Subhash C. Chauhan. Attenuation of Pancreatic Cancer Stemness and Growth by a Novel Magnetic Nanoparticle Formulation. *2014 PhDA Meeting Poster session, UTHSC Postdoc Research Day (Dec 10, 2014), Memphis, TN.*
 54. Mohammed Sikander, Neeraj Chauhan, Mohd S. Zaman, Shabnam Malik, **Murali M. Yallapu**, Meena Jaggi, Subhash C. Chauhan. Novel cucurbitacin analogue exhibits potent anti-cancer effects by targeting stemness through modulating tumor suppressor miRNA-145 expression in prostate cancer cells. Poster session, *7th Annual Postdoctoral research day at University of Tennessee Health Science Centre 2014 (December 10th), Memphis TN*
 55. Sheema Khan, Mara C. Ebeling, Mohd S. Zaman, Mohammed Sikander, **Murali M. Yallapu**, Neeraj Chauhan, Ashley M. Yacoubian, Stephen W. Behrman, Nadeem Zafar, Deepak Kumar, Paul A. Thompson, Meena Jaggi and Subhash C. Chauhan. Surgical management of complicated pancreatic pseudocysts following acute pancreatitis. *49th Annual Pancreas Club meeting, May 15-16, 2015, Washington, DC.*
 56. **Murali M. Yallapu**, Neeraj Chauhan, Sheema Khan, Meena Jaggi, Aditya Ganju, Diane M. Maher, Mara C. Ebeling, Subhash C. Chauhan. Novel pluronic F127-coated paclitaxel nanoparticles formulation for pancreatic cancer. 5534 Poster Session, *105 American Association of Cancer Research (AACR) Annual Meeting 2015 (April 18-22), Philadelphia, PA.*
 57. Mohd Saif Zaman, Neeraj Chauhan, Rishi K. Gara, Diane Maher, Sonam Kumari, Mohammed Sikander, Sheema Khan, **Murali M. Yallapu**, Meena Jaggi, Subhash C. Chauhan. Smoking Carcinogen (BaP) enhances tumorigenic phenotypes of cervical cancer cells by modulation of HPV oncogenes and microRNA profiles, 182 Poster Session, *105 American Association of Cancer Research (AACR) Annual Meeting 2015 (April 18-22), Philadelphia, PA.*
 58. Sheema Khan, **Murali M. Yallapu**, Sonam Kumari, Aditya Ganju, Swathi Balakrishna, Stephen W. Behrman, Nadeem Zafar, Meena Jaggi, Subhash C. Chauhan. Attenuation of pancreatic cancer stemness and growth by a novel magnetic nanoparticle formulation, 3676 Poster Session, *105 American Association of Cancer Research (AACR) Annual Meeting 2015 (April 18-22), Philadelphia, PA.*
 59. Sheema Khan, Neeraj Chauhan, **Murali M. Yallapu**, Mara C. Ebeling, Swathi Balakrishna, Robert T. Ellis, Paul A. Thompson, Stephen W. Behrman, Nadeem Zafar, Man M. Singh, Fathi T. Halaweish, Meena Jaggi, Subhash C. Chauhan. Generation of a novel ormeloxifene nanoparticle formulation for pancreatic cancer treatment, 4392 Poster Session. *105 American Association of Cancer Research (AACR) Annual Meeting 2015 (April 18-22), Philadelphia, PA.*
 60. Mohammed Sikander, Sheema Khan, Neeraj Chauhan, Mohd Saif Zaman, **Murali Mohan Yallapu**, Fathi T. Halaweish, Bhavin Chauhan, Shabnam Malik, Meena Jaggi, Subhash C. Chauhan. Anticancer activity of novel cucurbitacin analogue in pancreatic cancer, 4468 Poster Session, *105 American Association of Cancer Research (AACR) Annual Meeting 2015 (April 18-22), Philadelphia, PA.*

61. Gara RK, Kumari S, Ganju A, **Yallapu MM**, Shah A, Khan S, Singh MM, Chauhan SC and Jaggi M. Induction of Autophagy by ormeloxifene and mevastatin through protein kinase D1 in prostate cancer cells. 105 American Association of Cancer Research (AACR) Annual Meeting 2014 (April 5-9), San Diego CA.
62. Sikander M, Zaman MS, Chauhan N, **Yallapu MM**, Khan S, Halaweish FT, Chauhan B, Kumari S, Jaggi M and Chauhan SC. A multi-targeted approach for pancreatic cancer treatment by a novel cucurbitacin analogue. 105 American Association of Cancer Research (AACR) Annual Meeting 2014 (April 5-9), San Diego CA.
63. **Yallapu MM**, Chauhan N, Othman SF, Khalilzad-Sharghi V, Jaggi M and Chauhan SC. Characterization of a novel magnetic nanoparticles formulation for cancer therapeutic applications. 105 American Association of Cancer Research (AACR) Annual Meeting 2014 (April 5-9), San Diego CA.
64. Chauhan N, Zaman MS, Maher DM, Ebeling MC, **Yallapu MM**, Jaggi M and Chauhan SC. Ormeloxifene inhibits cervical cancer cell growth through intrinsic apoptotic pathway. 105 American Association of Cancer Research (AACR) Annual Meeting 2014 (April 5-9), San Diego CA.
65. Zaman MS, Chauhan N, Maher DM, **Yallapu MM**, Jaggi M and Chauhan SC. Curcumin nanoformulation. A new therapeutic approach for cervical cancer treatment. 105 American Association of Cancer Research (AACR) Annual Meeting 2014 (April 5-9), San Diego CA.
66. **Murali M. Yallapu**, Mara C. Ebeling, Sheema Khan, Neeraj Chauhan, Brij K. Gupta, Vasudha Sundram, Meena Jaggi, and Subhash C. Chauhan, Novel curcumin loaded magnetic nanoparticles for pancreatic cancer treatment. 104th AACR Annual Meeting 2013, Apr 6-10, 2013; Washington, DC
67. **Murali M. Yallapu**, Shadi F. Othman, Evan T. Curtis, Neeraj Chauhan, Nichole A. Bauer, Meena Jaggi, Subhash C. Chauhan, Curcumin loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications, 103rd AACR Annual Meeting 2012, Mar 31-Apr 4; Chicago, Illinois.
68. Neeraj Chauhan, Diane M. Maher, **Murali M. Yallapu**, Mara C. Ebeling, Meena Jaggi, Subhash C. Chauhan, Therapeutic effects of ormeloxifene on cervical cancer, 103rd AACR Annual Meeting 2012, Mar 31-Apr 4; Chicago, Illinois.
69. **Yallapu MM**, Othman SF, Curtis ET, Gupta BK, Jaggi M, and Chauhan SC, Multi-functional magnetic nanoparticles for theranostic applications, 102 AACR Annual Meeting 2011, April 2-6, 2011, Orange County Convention Center, Orlando, FL
70. **Yallapu MM.**, Ebeling M., Maher DM., Jaggi M. and Chauhan SC., Targeted curcumin delivery approach for improved prostate cancer therapeutics. DOD Innovative minds in prostate cancer therapy (IMPACT) Meeting 2011, March 9-12, 2011, The Hilton Orlando, FL
71. **Murali Mohan Yallapu**, Mara Ebeling, Diane Maher, Meena Jaggi, Subhash C Chauhan, Nano-curcumin for improved cancer therapeutics, Second Annual Sanford Health – USD Biomedical Research Symposium, May 11, 2011, Sanford Research, Sioux Falls, SD, USA
72. Neeraj Chauhan, Diane Maher, **Murali Mohan Yallapu**, Meena Jaggi, Subhash Chauhan, Therapeutic effects of ormeloxifene on cervical cancer, Second Annual Sanford Health – USD Biomedical Research Symposium, May 11, 2011, Sanford Research, Sioux Falls, SD, USA
73. Mitch R. Dobberpuhl, **Murali Mohan Yallapu**, Subhash C. Chauhan, Enhancing the efficacy of curcumin for prostate cancer treatment using cellulose nanoparticles, Medical Research Symposium, Aug 27, 2010, Vermillion, SD, USA.
74. **Murali M. Yallapu**, Brij Kumar Gupta, Meena Jaggi, Subhash C Chauhan, Curcumin loaded PLGA nanoparticles for cancer therapy, Sanford Health-USD Biomedical Medical Research Symposium, May 14, 2010, Vermillion, SD, USA.
75. Diane Maher, **Murali M. Yallapu**, Vasudha Sundram, Maria C. Bell, Meena Jaggi, Subhash C. Chauhan, Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth (Abstract No. 5381), 101st Annual Meeting of the American Association for Cancer Research, Apr 17-21, 2010; Washington, DC. Philadelphia (PA), USA.
76. **Murali M. Yallapu**, Meena Jaggi, Subhash C. Chauhan, Design of β -cyclodextrin-curcumin self-assembly: A new approach for enhanced curcumin delivery and therapeutic efficacy in prostate cancer cells, 101st Annual Meeting of the American Association for Cancer Research, Apr 17-21, 2010; Washington, DC. Philadelphia (PA), USA,
77. K. Vimala, K. Varaprasad, S. Ravindra, N. Narayana Reddy, **Y. Murali Mohan**, K. Mohana Raju, Development of chitosan-PVA films with antimicrobial silver nanoparticles (IL 171), International Conference on Nanomaterials: Synthesis, Characterization and Applications (ICN-2010), April 27-28, 2010, Mahatma Gandhi University, Kottayam, Kerala, India.

78. N. Narayana Reddy, **Y. Murali Mohan**, K. Varaprasad, S. Ravindra, M. Penchel Reddy, P.A. Joy, and K. Mohana Raju, Magnetic and electric responsive hydrogel-magnetic nanocomposites: Synthesis, characterization and drug delivery applications, National Conference on Advances in Nanoscience and Technology (NANOSAT-10) April 22& 23, 2010, Amal Jyothi College of Engineering, Kerala, India.
79. K. Varaprasad, **Y. Murali Mohan**, S. Ravindra, N. Narayana Reddy, K. Vimala, B. Sreedhar, and K. Mohana Raju, Antibacterial silver nanoparticles embedded in semi-IPN hydrogel nanocomposites (P31), Recent Advances in Polymeric Materials, MACRO 2009, 10th National Conference of The Society of Polymer Science, Chennai Chapter, Indian Institute of Technology, India, March 9-11, 2009.
80. K. Vimala, K. Varaprasad, S. Ravindra, N. Narayana Reddy, **Y. Murali Mohan**, and K. Mohana Raju, Development of Poly(acrylamide)/Poly(ethylene glycol) semi-IPN hydrogel silver nanocomposites for antibacterial applications (P82), Recent Advances in Polymeric Materials, MACRO 2009, 10th National Conference of The Society of Polymer Science, Chennai Chapter, Indian Institute of Technology, India, March 9-11, 2009.

Invited/Oral Lectures:

1. “Nanotechnology in Cancer Treatment”, Dr. Murali Yallapu, Jan 23, 2020, EEDUC 1.102, Spring Biology Seminar Series, College of Sciences, UTRGV, Edinburg.
<https://www.utrgv.edu/biology/news/seminars/index.htm>
2. Nutraceutical delivery using nanoparticles, 3rd International Conference on Nutraceuticals and Chronic Diseases (3rd INCD-2018), September 14th-17th, 2018, Dehradun, UK, India, Podium presentation
3. Nutraceutical (Tannin)-paclitaxel self-assemblies for breast cancer, 2nd International Conference on Nutraceuticals and Chronic Diseases (2nd INCD-2017), September 1st - 3rd, 2017, Bogmallo, Goa, India. Podium presentation
4. Emerging Trends in Pharmacy, Raghavendra Institute of Pharmaceutical Education and Research (RIPER), Sept 5, 2017. Anantapur, AP, India.
5. Therapeutic Nanoformulations: Design to Therapy, International Symposium “New Strategies in Nanotechnology Research for Biomedical Applications” Organized by CIPA & USS, 12th March 2018, Concepcion, Chile. Inaugural lecture.
6. 2nd International Conference on Nutraceuticals and Chronic Diseases (2nd INCD-2017), September 1st - 3rd, 2017, Bogmallo, Goa, India. Moderator of a September 3rd Morning Session,
7. PSMA targeted Docetaxel nanoparticles, Memphis Biomaterials Day 2016, March 18th 2016 Department of Biomedical Engineering, FedEx Auditorium, University of Memphis, TN, USA.
8. Magnetic Nanoparticles: Design to Therapeutics, April 25, 2016, Center for Cancer Research--Auditorium, University of Tennessee Health Science Center, Memphis, TN, USA
9. Magnetic Nanoparticles: Design to Therapeutic Applications, Feb 23, 2016, Department of Chemistry-Auditorium, University of Memphis, TN, USA
10. Protein corona on magnetic nanoparticle, 2015 Joint Southeastern/Southwest Regional Meeting, Cook Convention Center, Mississippi Room, November 4-7, 2015.
11. Implications of protein corona on physico-chemical and biological properties of magnetic nanoparticles, March 23, 2015, 2.45-3.00 PM, Ball room C, Biomaterials Research Day 2015, Vanderbilt Student Life Center, Vanderbilt University, Nashville, TN.
12. Multi-layer Magnetic Nanoparticles for Drug Delivery and Imaging, Department of Physics, University of Memphis Physics Seminar Schedule (Feb 13, 2015, 3.00-4.00 pm, Venue: Manning Hall # 201 (Physics Auditorium), Memphis, TN.
13. Advances in Nanotechnology and Drug Delivery, Department of Pharmaceutical Sciences, The University of Tennessee Health Science Center (09/08/2014), College of Pharmacy Bld., Room 105, Memphis, TN.

Service:

- a. Tara oak Elementary School visit on Educational Activities and Science Exhibition, 2018
- b. Houston High School, Tennessee Promise Mentor, 2018 (group of High School Students)
- c. Lab research updates with *Pancreatic Cancer patients and Kosten Foundation members*, Memphis, TN, (half-yearly) and meeting with Kosten Foundation Group.
- d. Participated/Involved in 5K Run April 2014-2019